Cancer immunotherapy: the beginning of the end of can

BMC Medicine

14, 73

DOI: 10.1186/s12916-016-0623-5

Citation Report

#	Article	IF	Citations
1	Cancer Metabolism: Fueling More than Just Growth. Molecules and Cells, 2016, 39, 847-854.	1.0	75
2	Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment. Vaccines, 2016, 4, 41.	2.1	44
3	Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma. Cancers, 2016, 8, 87.	1.7	30
4	The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. ESMO Open, 2016, 1, e000122.	2.0	55
5	Reframing the â€œCancer Moonshotâ€• EMBO Reports, 2016, 17, 1685-1687.	2.0	4
6	Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?. Respiratory Medicine Case Reports, 2016, 19, 118-120.	0.2	10
7	Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs. Veterinary Immunology and Immunopathology, 2016, 182, 95-100.	0.5	14
8	Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports, 2016, 6, 35848.	1.6	127
9	A novel non-Hodgkin lymphoma murine model closer to the standard clinical scenario. Journal of Translational Medicine, 2016, 14, 323.	1.8	15
10	Immunotherapy with radiotherapy in urological malignancies. Current Opinion in Urology, 2016, 26, 514-522.	0.9	5
11	Targeting the Lung Cancer Microenvironment: Harnessing Host Responses. , 2017, , 309-327.		1
12	Targeting iNOS to increase efficacy of immunotherapies. Human Vaccines and Immunotherapeutics, 2017, 13, 1105-1108.	1.4	49
13	Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis. Clinical Immunology, 2017, 179, 8-16.	1.4	44
14	The role of lymph node size and FOXP3+ regulatory T cells in node-negative colon cancer. Journal of Clinical Pathology, 2017, 70, 443-447.	1.0	10
15	Cancer-immune therapy: restoration of immune response in cancer by immune cell modulation. Nucleus (India), 2017, 60, 93-109.	0.9	4
16	The expanding role of immunotherapy. Cancer Treatment Reviews, 2017, 54, 74-86.	3.4	100
17	Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. Expert Opinion on Biological Therapy, 2017, 17, 515-523.	1.4	60
18	Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 41-54.	3.3	55

#	Article	IF	Citations
19	A new therapeutic potential for cancers: One CAR with 2 different engines!. Human Vaccines and Immunotherapeutics, 2017, 13, 1786-1788.	1.4	4
20	The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade. Annals of Oncology, 2017, 28, 1934-1941.	0.6	76
21	Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. OncoImmunology, 2017, 6, e1310358.	2.1	111
22	Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. OncoImmunology, 2017, 6, e1326442.	2.1	48
23	Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. Journal of Medicinal Chemistry, 2017, 60, 5857-5867.	2.9	242
24	Immunotherapy for head and neck cancer: the future of treatment?. Expert Opinion on Biological Therapy, 2017, 17, 701-708.	1.4	24
25	The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities. Targeted Oncology, 2017, 12, 139-152.	1.7	31
26	Tumor Immunology Viewed from Alternative Animal Modelsâ€"the Xenopus Story. Current Pathobiology Reports, 2017, 5, 49-56.	1.6	10
27	Immunomonitoring reveals interruption of anergy after vaccination in a case of type-2-papillary renal cell carcinoma. Immunotherapy, 2017, 9, 319-329.	1.0	3
28	The Role of Targeted Therapy in the Management of Sinonasal Malignancies. Otolaryngologic Clinics of North America, 2017, 50, 443-455.	0.5	12
29	Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death and Disease, 2017, 8, e3004-e3004.	2.7	90
30	mTOR co-targeting strategies for head and neck cancer therapy. Cancer and Metastasis Reviews, 2017, 36, 491-502.	2.7	46
31	Check point inhibitors as therapies for infectious diseases. Current Opinion in Immunology, 2017, 48, 61-67.	2.4	38
32	Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission. Endocrine-Related Cancer, 2017, 24, T311-T329.	1.6	23
33	Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy. Therapeutic Advances in Cardiovascular Disease, 2017, 11, 297-317.	1.0	16
34	Patent trend and competitive analysis of cancer immunotherapy in the United States. Human Vaccines and Immunotherapeutics, 2017, 13, 2583-2593.	1.4	6
35	Immunotherapies for advanced melanoma: as promising as they are expensive?. Journal of the Royal Society of Medicine, 2017, 110, 395-399.	1.1	2
36	The immune response to secondary necrotic cells. Apoptosis: an International Journal on Programmed Cell Death, 2017, 22, 1189-1204.	2.2	198

#	Article	IF	Citations
37	How and when adjuvant treatment should be intensified in stage III colorectal cancers?. Future Oncology, 2017, 13, 1999-2006.	1.1	2
38	Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms. Nature Communications, 2017, 8, 344.	5.8	61
39	Current status and future prospects for human papillomavirus vaccines. Archives of Pharmacal Research, 2017, 40, 1050-1063.	2.7	40
40	Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone. Clinical Orthopaedics and Related Research, 2017, 475, 3071-3081.	0.7	14
41	Immunotherapy advances for mesothelioma treatment. Expert Review of Anticancer Therapy, 2017, 17, 799-814.	1.1	12
42	Patient-Derived Xenografts as Cancer Models for Preclinical Drug Screening. Molecular and Translational Medicine, 2017, , 141-154.	0.4	1
43	Effects of Affordable Care Act Marketplaces and Medicaid Eligibility Expansion on Access to Cancer Care. Cancer Journal (Sudbury, Mass), 2017, 23, 168-174.	1.0	16
44	The PI3K Pathway in Human Disease. Cell, 2017, 170, 605-635.	13.5	1,702
45	Systemic virotherapy for multiple myeloma. Expert Opinion on Biological Therapy, 2017, 17, 1-13.	1.4	11
46	Clusters of circulating tumor cells: A biophysical and technological perspective. Current Opinion in Biomedical Engineering, 2017, 3, 13-19.	1.8	32
47	Young donor white blood cell immunotherapy induces extensive tumor necrosis in advanced-stage solid tumors. Heliyon, 2017, 3, e00438.	1.4	9
48	Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. Expert Opinion on Investigational Drugs, 2017, 26, 933-944.	1.9	11
49	The safety of nivolumab for the treatment of metastatic melanoma. Expert Opinion on Drug Safety, 2017, 16, 955-961.	1.0	7
50	Cytokines in immunogenic cell death: Applications for cancer immunotherapy. Cytokine, 2017, 97, 123-132.	1.4	226
51	Immunotherapy of Prostate Cancer: Facts and Hopes. Clinical Cancer Research, 2017, 23, 6764-6770.	3.2	173
52	Emerging links among Chromosome Instability (CIN), cancer, and aging. Molecular Carcinogenesis, 2017, 56, 791-803.	1.3	22
53	Potential applications of nanoparticles in cancer immunotherapy. Human Vaccines and Immunotherapeutics, 2017, 13, 63-74.	1.4	35
54	Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance. Oncotarget, 2017, 8, 70982-71001.	0.8	42

#	Article	IF	Citations
55	Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies. Frontiers in Pharmacology, 2017, 8, 295.	1.6	74
56	Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma. International Journal of Molecular Sciences, 2017, 18, 2732.	1.8	26
57	Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmetteâ€“Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. Frontiers in Immunology, 2017, 8, 625.	2.2	56
58	Molecular Imaging: A Useful Tool for the Development of Natural Killer Cell-Based Immunotherapies. Frontiers in Immunology, 2017, 8, 1090.	2.2	40
59	Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumorâ€“Host Interaction and Therapeutic Perspectives. Frontiers in Immunology, 2017, 8, 1526.	2.2	74
60	Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. Frontiers in Immunology, 2017, 8, 1617.	2.2	43
61	New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Frontiers in Immunology, 2017, 8, 1804.	2.2	54
62	Advances in Immunotherapy for Melanoma: A Comprehensive Review. Mediators of Inflammation, 2017, 2017, 1-14.	1.4	92
63	Evolutionary Perspective of Tumorigenesis and Antitumor Immunity: A Comparative Approach. , 2017, , 119-135.		1
64	Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma. OncoTargets and Therapy, 2017, Volume 10, 5745-5754.	1.0	14
65	S-Nitrosothiol Metabolism in Cancer and Therapeutic Implications. , 2017, , 211-222.		0
66	Circulating tumor DNA for personalized lung cancer monitoring. BMC Medicine, 2017, 15, 157.	2.3	10
67	CSPG4: a prototype oncoantigen for translational immunotherapy studies. Journal of Translational Medicine, 2017, 15, 151.	1.8	51
68	Identification of new MUC1 epitopes using HLA-transgenic animals: implication for immunomonitoring. Journal of Translational Medicine, 2017, 15, 154.	1.8	4
69	Cellular immunity augmentation in mainstream oncologic therapy. Cancer Biology and Medicine, 2017, 14, 121.	1.4	8
70	Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget, 2017, 8, 48436-48452.	0.8	216
71	Viroimmunotherapy for Colorectal Cancer: Clinical Studies. Biomedicines, 2017, 5, 11.	1.4	25
72	Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines, 2017, 5, 3.	1.4	29

#	Article	IF	Citations
73	Brain metastases from hepatocellular carcinoma: recent advances and future avenues. Oncotarget, 2017, 8, 25814-25829.	0.8	27
74	Targeting complement-mediated immunoregulation for cancer immunotherapy. Seminars in Immunology, 2018, 37, 85-97.	2.7	44
75	Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential. Expert Opinion on Biological Therapy, 2018, 18, 449-457.	1.4	25
76	Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. Future Oncology, 2018, 14, 1869-1874.	1.1	31
77	Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). International Journal of Oncology, 2018, 52, 1041-1056.	1.4	4
78	Anticancer Mechanisms in Two Murine Bone Marrowâ€“Derived Dendritic Cell Subsets Activated with TLR4 Agonists. Journal of Immunology, 2018, 200, 2656-2669.	0.4	8
79	Antitumor activity and carrier properties of novel hemocyanins coupled to a mimotope of GD2 ganglioside. European Journal of Medicinal Chemistry, 2018, 150, 74-86.	2.6	11
80	Specific blockade <scp>CD</scp>73 alters the â€œexhaustedâ€•phenotype of <scp>T</scp> cells in head and neck squamous cell carcinoma. International Journal of Cancer, 2018, 143, 1494-1504.	2.3	31
81	Immunostimulation and Immunosuppression: Nanotechnology on the Brink. Small Methods, 2018, 2, 1700347.	4.6	32
82	Oncogenesis as a Selective Force: Adaptive Evolution in the Face of a Transmissible Cancer. BioEssays, 2018, 40, 1700146.	1.2	18
83	Cell membrane-coated nanocarriers: the emerging targeted delivery system for cancer theranostics. Drug Discovery Today, 2018, 23, 891-899.	3.2	112
84	Low-molecular-weight polysaccharides from AgaricusÃ¯Â¿Â½blazei Murrill modulate the Th1 response in cancer immunity. Oncology Letters, 2018, 15, 3429-3436.	0.8	15
85	Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death and Disease, 2018, 9, 115.	2.7	408
86	Immunotherapy using regulatory T cells in cancer suggests more flavors of hypersensitivity type IV. Immunotherapy, 2018, 10, 213-219.	1.0	0
87	Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras. Cancer Immunology, Immunotherapy, 2018, 67, 589-603.	2.0	10
88	Challenging Standard-of-Care Paradigms in the Precision Oncology Era. Trends in Cancer, 2018, 4, 101-109.	3.8	56
89	Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model. Cancer Immunology, Immunotherapy, 2018, 67, 653-662.	2.0	11
90	From a Patient Advocateâ€™s Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?. Current Oncology Reports, 2018, 20, 8.	1.8	20

#	Article	IF	Citations
91	Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis. Cancer Immunology, Immunotherapy, 2018, 67, 713-727.	2.0	68
92	Exosomesâ€"Small Players, Big Sound. Bioconjugate Chemistry, 2018, 29, 635-648.	1.8	35
93	Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy. Cancer and Metastasis Reviews, 2018, 37, 45-53.	2.7	30
94	Immunogenic Stress and Death of Cancer Cells in Natural and Therapy-Induced Immunosurveillance. , 2018, , 215-229.		9
95	Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care. ACS Nano, 2018, 12, 24-43.	7.3	192
96	Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. Seminars in Cancer Biology, 2018, 52, 26-38.	4.3	49
97	Antibodyâ€drug conjugates: Promising and efficient tools for targeted cancer therapy. Journal of Cellular Physiology, 2018, 233, 6441-6457.	2.0	67
98	Immunotherapy for brain tumors: understanding early successes and limitations. Expert Review of Neurotherapeutics, 2018, 18, 251-259.	1.4	22
99	Cell Membrane Bioconjugation and Membrane-Derived Nanomaterials for Immunotherapy. Bioconjugate Chemistry, 2018, 29, 624-634.	1.8	37
100	Immunoengineering with biomaterials for enhanced cancer immunotherapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2018, 10, e1506.	3.3	33
101	Therapeutic Targets of FDA-Approved Immunotherapies in Oncology. , 2018, , 21-37.		3
102	CHECKPOINT INHIBITOR IMMUNE THERAPY. Retina, 2018, 38, 1063-1078.	1.0	252
103	Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2018, 105, 1621-1626.	0.7	5
104	HDAC inhibitors as epigenetic regulators for cancer immunotherapy. International Journal of Biochemistry and Cell Biology, 2018, 98, 65-74.	1.2	61
105	Armed oncolytic viruses: A kick-start for anti-tumor immunity. Cytokine and Growth Factor Reviews, 2018, 41, 28-39.	3.2	110
106	Novel targeted therapies and immunotherapy for advanced thyroid cancers. Molecular Cancer, 2018, 17, 51.	7.9	168
107	Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. Oncologist, 2018, 23, 936-942.	1.9	69
108	Genetic Regulatory Mechanisms of Evolution and Embryogenesis in a Distorting Mirror of Carcinogenesis. Russian Journal of Genetics, 2018, 54, 145-156.	0.2	4

#	Article	IF	Citations
109	Companion and Complementary Diagnosticsâ€“Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Nonâ€“Small Cell Lung Cancer. Therapeutic Drug Monitoring, 2018, 40, 9-16.	1.0	82
110	CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cellular and Molecular Life Sciences, 2018, 75, 689-713.	2.4	351
111	Prognostic impact of preâ€treatment neutrophilâ€toâ€lymphocyte ratio (<scp>NLR</scp>) in nasopharyngeal carcinoma: A retrospective study of 180 Taiwanese patients. Clinical Otolaryngology, 2018, 43, 463-469.	0.6	20
112	Detection of ABCB5 tumour antigen-specific CD8+ T cells in melanoma patients and implications for immunotherapy. Clinical and Experimental Immunology, 2017, 191, 74-83.	1.1	5
113	Organotypic three-dimensional assays based on human leiomyomaâ€“derived matrices. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20160482.	1.8	26
114	Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy. Journal of Cellular Physiology, 2018, 233, 5189-5199.	2.0	65
115	Metallic nanoparticles for cancer immunotherapy. Materials Today, 2018, 21, 673-685.	8.3	164
116	CAR-T cells and combination therapies: Whatâ€™s next in the immunotherapy revolution?. Pharmacological Research, 2018, 129, 194-203.	3.1	33
117	Drug development in the era of precision medicine. Nature Reviews Drug Discovery, 2018, 17, 183-196.	21.5	294
118	Breast cancer genomics and immuno-oncological markers to guide immune therapies. Seminars in Cancer Biology, 2018, 52, 178-188.	4.3	111
119	State of the Art Treatment and Surveillance Imaging of Glioblastomas. Seminars in Roentgenology, 2018, 53, 23-36.	0.2	7
120	Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model. World Journal of Clinical Oncology, 2018, 9, 188-199.	0.9	3
121	New Strategies to Improve Therapeutic Vaccines. , 0, , .		1
122	Dramatic Response of a PD-L1â€“Positive Advanced Angiosarcoma of the Scalp to Pembrolizumab. JCO Precision Oncology, 2018, 2, 1-7.	1.5	16
123	Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight, 2018, 3, .	2.3	137
124	Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma. Journal of Immunology Research, 2018, 2018, 1-12.	0.9	11
125	Investigation of Interleukin-27 in the Sera of Nonmelanoma Skin Cancer Patients. Dermatology Research and Practice, 2018, 2018, 1-5.	0.3	1
126	Comparative Transcriptomics Unravels Prodigiosin's Potential Cancer-Specific Activity Between Human Small Airway Epithelial Cells and Lung Adenocarcinoma Cells. Frontiers in Oncology, 2018, 8, 573.	1.3	11

#	Article	IF	Citations
127	Treating osteosarcoma with CAR T cells. Scandinavian Journal of Immunology, 2019, 89, e12741.	1.3	36
128	Immune-Related Adverse Events: Pneumonitis. Advances in Experimental Medicine and Biology, 2018, 995, 131-149.	0.8	19
129	Bioactive Nanoparticles for Cancer Immunotherapy. International Journal of Molecular Sciences, 2018, 19, 3877.	1.8	82
130	Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 466-479.	2.7	15
131	Monoclonal antibodies in cancer immunotherapy. Molecular Biology Reports, 2018, 45, 2935-2940.	1.0	142
132	Immunotherapy of alveolar echinococcosis via <scp>PD</scp>â€1/<scp>PD</scp>â€L1 immune checkpoint blockade in mice. Parasite Immunology, 2018, 40, e12596.	0.7	42
133	A Nobel Prizeâ€worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens. Immunology, 2018, 155, 283-284.	2.0	53
134	An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules. PLoS ONE, 2018, 13, e0205491.	1.1	53
135	Regulatory perspective on in vitro potency assays for human dendritic cells used in anti-tumor immunotherapy. Cytotherapy, 2018, 20, 1289-1308.	0.3	9
136	From Cancer Immunoediting to New Strategies in Cancer Immunotherapy: The Roles of Immune Cells and Mechanics in Oncology. Advances in Experimental Medicine and Biology, 2018, 1092, 113-138.	0.8	19
137	Regulation of the master regulator FOXM1 in cancer. Cell Communication and Signaling, 2018, 16, 57.	2.7	241
138	Introduction to the Special Collectionâ€"Beating Cancer with Early Detection: A Seasoned Idea with New Insights. journal of applied laboratory medicine, The, 2018, 3, 155-158.	0.6	0
139	Immunoengineering through cancer vaccines â€“ A personalized and multi-step vaccine approach towards precise cancer immunity. Journal of Controlled Release, 2018, 289, 125-145.	4.8	31
140	Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. Current Rheumatology Reports, 2018, 20, 65.	2.1	39
141	Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cellular and Molecular Life Sciences, 2018, 75, 4151-4162.	2.4	150
142	Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic. Biomedicines, 2018, 6, 14.	1.4	66
143	Immunopharmacogenomics in Cancer Management. , 0, , .		1
144	Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics. Glycobiology, 2018, 28, 697-712.	1.3	8

#	Article	IF	Citations
145	Development of mRNA vaccines and their prophylactic and therapeutic applications. Nano Research, 2018, 11, 5173-5192.	5.8	18
146	Randomized clinical trials and personalized medicine: A commentary on deaton and cartwright. Social Science and Medicine, 2018, 210, 71-73.	1.8	27
147	T Lymphocyteâ€"Based Cancer Immunotherapeutics. International Review of Cell and Molecular Biology, 2018, 341, 201-276.	1.6	22
148	Exploring the links between cancer and placenta development. Open Biology, 2018, 8, .	1.5	109
149	A potentially important role for T cells and regulatory T cells in Langerhans cell histiocytosis. Clinical Immunology, 2018, 194, 19-25.	1.4	12
150	Personalized medicine: motivation, challenges, and progress. Fertility and Sterility, 2018, 109, 952-963.	0.5	294
151	Increased tumor vascularization is associated with the amount of immune competent PDâ€'1 positive cells in testicular germ cell tumors. Oncology Letters, 2018, 15, 9852-9860.	0.8	13
152	A multi-functional macrophage and tumor targeting gene delivery system for the regulation of macrophage polarity and reversal of cancer immunoresistance. Nanoscale, 2018, 10, 15578-15587.	2.8	51
153	Nanoimmunotherapy â€" cloaked defenders to breach the cancer fortress. Nanotechnology Reviews, 2018, 7, 317-340.	2.6	8
154	Immuno-Oncology: Emerging Targets and Combination Therapies. Frontiers in Oncology, 2018, 8, 315.	1.3	244
155	Lymphatic vessel density is associated with CD8⁺ T cell infiltration and immunosuppressive factors in human melanoma. OncoImmunology, 2018, 7, e1462878.	2.1	47
156	Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based chemoimmunotherapy. Journal of Experimental and Clinical Cancer Research, 2018, 37, 126.	3.5	24
157	Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells. Journal of Experimental and Clinical Cancer Research, 2018, 37, 168.	3.5	72
158	Improving the Subcutaneous Mouse Tumor Model by Effective Manipulation of Magnetic Nanoparticles-Treated Implanted Cancer Cells. Annals of Biomedical Engineering, 2018, 46, 1975-1987.	1.3	4
159	Robust method for isolation of tumor infiltrating lymphocytes with a high vital cell yield from small samples of renal cell carcinomas by a new collagenase-free mechanical procedure. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 402.e1-402.e10.	0.8	5
160	Salmonella Immunotherapy Improves the Outcome of CHOP Chemotherapy in Non-Hodgkin Lymphoma-Bearing Mice. Frontiers in Immunology, 2018, 9, 7.	2.2	33
161	A Novel Three-Dimensional Immune Oncology Model for High-Throughput Testing of Tumoricidal Activity. Frontiers in Immunology, 2018, 9, 857.	2.2	57
162	Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. Frontiers in Immunology, 2018, 9, 1310.	2.2	404

#	Article	IF	Citations
163	The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis. Frontiers in Oncology, 2018, 8, 27.	1.3	71
164	Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice. Frontiers in Oncology, 2018, 8, 80.	1.3	40
165	Optimization of combination therapy for chronic myeloid leukemia with dosing constraints. Journal of Mathematical Biology, 2018, 77, 1533-1561.	0.8	7
166	Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field. Journal of Clinical Medicine, 2018, 7, 41.	1.0	77
167	Synthesis of New Benzothiazole Acylhydrazones as Anticancer Agents. Molecules, 2018, 23, 1054.	1.7	54
168	Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma. Immunotherapy, 2018, 10, 779-786.	1.0	58
169	Crystal structure of an L chain optimised 14F7 anti-ganglioside Fv suggests a unique tumour-specificity through an unusual H-chain CDR3 architecture. Scientific Reports, 2018, 8, 10836.	1.6	8
170	A Robust Approach to Sample Size Calculation in Cancer Immunotherapy Trials with Delayed Treatment Effect. Biometrics, 2018, 74, 1292-1300.	0.8	13
171	Additional Insights into Hypericum perforatum Content: Isolation, Total Synthesis, and Absolute Configuration of Hyperbiphenyls A and B from Immunomodulatory Root Extracts. Journal of Natural Products, 2018, 81, 1850-1859.	1.5	5
172	Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors. Frontiers in Cell and Developmental Biology, 2018, 6, 38.	1.8	171
173	Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment. Frontiers in Cell and Developmental Biology, 2018, 6, 56.	1.8	54
174	CD206â€positive myeloid cells bind galectinâ€9 and promote a tumorâ€supportive microenvironment. Journal of Pathology, 2018, 245, 468-477.	2.1	41
175	Transgelin-2 in immunity: Its implication in cell therapy. Journal of Leukocyte Biology, 2018, 104, 903-910.	1.5	26
176	New Directions in the Study and Treatment of Metastatic Cancer. Frontiers in Oncology, 2018, 8, 258.	1.3	14
177	The role of automated cytometry in the newï¿½era of cancer immunotherapy (Review). Molecular and Clinical Oncology, 2018, 9, 355-361.	0.4	12
178	Checkpoint inhibition in the treatment of multiple myeloma: A way to boost innate-like T cell anti-tumor function?. Molecular Immunology, 2018, 101, 521-526.	1.0	6
179	Applications of tumor chip technology. Lab on A Chip, 2018, 18, 2893-2912.	3.1	86
180	Mammalia: Proboscidea: Elephant Immune System. , 2018, , 863-883.		1

#	Article	IF	Citations
181	New Hopes for Plasma-Based Cancer Treatment. Plasma, 2018, 1, 150-155.	0.7	35
182	Development of a new highâ€affinity human antibody with antitumor activity against solid and blood malignancies. FASEB Journal, 2018, 32, 5063-5077.	0.2	7
183	Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New. Mayo Clinic Proceedings, 2018, 93, 917-936.	1.4	4
184	Recent progress in therapeutic antibodies for cancer immunotherapy. Current Opinion in Chemical Biology, 2018, 44, 56-65.	2.8	21
185	Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect. Immunology Letters, 2018, 200, 33-42.	1.1	19
186	Computational Characterization of Suppressive Immune Microenvironments in Glioblastoma. Cancer Research, 2018, 78, 5574-5585.	0.4	53
187	Obesity-Induced Defects in Dendritic Cell and T Cell Functions. , 2018, , 171-181.		1
188	Miracles and cancer immunotherapy: An in-depth look at medical miracles. Independent Nurse, 2019, 2019, 13-15.	0.0	0
189	Are mimotope vaccines a good alternative to monoclonal antibodies?. Immunotherapy, 2019, 11, 795-800.	1.0	9
190	CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8+ T-cell responses by upregulating MHC-I expression. Oncogene, 2019, 38, 7166-7180.	2.6	38
191	Expression of the immune checkpoint receptor TIGIT in seminoma. Oncology Letters, 2019, 18, 1497-1502.	0.8	7
192	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
193	Enhanced early immune response of leptospiral outer membrane protein LipL32 stimulated by narrow band mid-infrared exposure. Journal of Photochemistry and Photobiology B: Biology, 2019, 198, 111560.	1.7	6
194	Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Science Translational Medicine, 2019, 11, .	5.8	147
195	Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. Cancer Immunology, Immunotherapy, 2019, 68, 1351-1358.	2.0	24
196	Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy. Cell Reports, 2019, 28, 819-831.e4.	2.9	91
197	Small-Molecule Poly(ADP-ribose) Polymerase and PD-L1 Inhibitor Conjugates as Dual-Action Anticancer Agents. ACS Omega, 2019, 4, 12584-12597.	1.6	19
198	Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy. Cancer Research, 2019, 79, 4149-4159.	0.4	44

#	Article	IF	Citations
199	Cell cytotoxicity, immunostimulatory and antitumor effects of lipid content of liposomal delivery platforms in cancer immunotherapies. A comprehensive in-vivo and in-vitro study. International Journal of Pharmaceutics, 2019, 567, 118492.	2.6	21
200	Antiviral interferons induced by Newcastle disease virus (NDV) drive a tumor-selective apoptosis. Scientific Reports, 2019, 9, 15160.	1.6	15
201	Increased cytoplasmatic expression of cancer immune surveillance receptor CD1d in anaplastic thyroid carcinomas. Cancer Medicine, 2019, 8, 7065-7073.	1.3	7
202	Multiantigenic Nanoformulations Activate Anticancer Immunity Depending on Size. Advanced Functional Materials, 2019, 29, 1903391.	7.8	34
203	Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance. International Journal of Biological Markers, 2019, 34, 398-405.	0.7	34
204	Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells. BMC Veterinary Research, 2019, 15, 339.	0.7	7
205	A concise review on cancer treatment methods and delivery systems. Journal of Drug Delivery Science and Technology, 2019, 54, 101350.	1.4	60
206	Chemically engineered glycan-modified cancer vaccines to mobilize skin dendritic cells. Current Opinion in Chemical Biology, 2019, 53, 167-172.	2.8	9
207	Multifunctional Glycoconjugates for Recruiting Natural Antibodies against Cancer Cells. Chemistry - A European Journal, 2019, 25, 15508-15515.	1.7	22
208	A nomogram based on a gene signature for predicting the prognosis of patients with head and neck squamous cell carcinoma. International Journal of Biological Markers, 2019, 34, 309-317.	0.7	6
209	Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nature Communications, 2019, 10, 3991.	5.8	409
210	Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. Blood, 2019, 134, 1406-1414.	0.6	80
211	Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. Cells, 2019, 8, 1083.	1.8	153
212	Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies. Antioxidants, 2019, 8, 407.	2.2	40
213	Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors. International Journal of Molecular Sciences, 2019, 20, 4654.	1.8	29
214	Cancer Stem Cells Targeting; the Lessons from the Interaction of the Immune System, the Cancer Stem Cells and the Tumor Niche. International Reviews of Immunology, 2019, 38, 267-283.	1.5	12
215	Development of a Nursing Policy for the Administration of an Oncolytic Virus in the Outpatient Setting. Seminars in Oncology Nursing, 2019, 35, 150928.	0.7	2
216	Patient Education Issues and Strategies Associated With Immunotherapy. Seminars in Oncology Nursing, 2019, 35, 150933.	0.7	13

#	Article	IF	Citations
217	Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development. Current Oncology Reports, 2019, 21, 2.	1.8	42
218	The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer. International Journal of Molecular Sciences, 2019, 20, 501.	1.8	39
219	Applications of SNAPâ€tag technology in skin cancer therapy. Health Science Reports, 2019, 2, e103.	0.6	4
220	Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovascular Research, 2019, 115, 854-868.	1.8	311
221	Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. Clinical Science, 2019, 133, 181-193.	1.8	51
222	Intrinsic cancer vaccination. Advanced Drug Delivery Reviews, 2019, 151-152, 2-22.	6.6	30
223	A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DARTÂ®. AAPS Journal, 2019, 21, 66.	2.2	45
224	The concurrent effects of azurin and Mammaglobin-A genes in inhibition of breast cancer progression and immune system stimulation in cancerous BALB/c mice. 3 Biotech, 2019, 9, 271.	1.1	4
225	Evolutionary Underpinnings of Innate-Like T Cell Interactions with Cancer. Immunological Investigations, 2019, 48, 737-758.	1.0	6
226	Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer. Nature Communications, 2019, 10, 2764.	5.8	166
227	High Salt Inhibits Tumor Growth by Enhancing Anti-tumor Immunity. Frontiers in Immunology, 2019, 10, 1141.	2.2	34
228	Significance of PDâ€'L1 clones and Câ€'MET expression in hepatocellular carcinoma. Oncology Letters, 2019, 17, 5487-5498.	0.8	9
229	Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development. Antibodies, 2019, 8, 34.	1.2	10
230	The Evolving Role of CD8+CD28â^' Immunosenescent T Cells in Cancer Immunology. International Journal of Molecular Sciences, 2019, 20, 2810.	1.8	105
231	Tumor Lymphatic Function Regulates Tumor Inflammatory and Immunosuppressive Microenvironments. Cancer Immunology Research, 2019, 7, 1345-1358.	1.6	31
232	TGF-Î²-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. International Journal of Molecular Sciences, 2019, 20, 2767.	1.8	635
233	Combination of pentoxifylline and Î±-galactosylceramide with radiotherapy promotes necro-apoptosis and leukocyte infiltration and reduces the mitosis rate in murine melanoma. Acta Histochemica, 2019, 121, 680-689.	0.9	4
234	Evaluation of Formalin Fixation for Tissue Biopsies Using Shear Wave Laser Speckle Imaging System. IEEE Journal of Translational Engineering in Health and Medicine, 2019, 7, 1-10.	2.2	4

#	Article	IF	Citations
235	Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis. Progress in Retinal and Eye Research, 2019, 72, 100761.	7.3	37
236	The Role of Organic Synthesis in the Emergence and Development of Antibodyâ€“Drug Conjugates as Targeted Cancer Therapies. Angewandte Chemie - International Edition, 2019, 58, 11206-11241.	7.2	75
237	A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Molecular Cancer Therapeutics, 2019, 18, 1081-1091.	1.9	43
238	Die Bedeutung der organischen Synthese bei der Entstehung und Entwicklung von AntikÃ¶rperâ€Wirkstoffâ€Konjugaten als gezielte Krebstherapien. Angewandte Chemie, 2019, 131, 11326-11363.	1.6	11
239	MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. Journal of Controlled Release, 2019, 303, 223-236.	4.8	58
240	Exploring designability of electrostatic complementarity at an antigen-antibody interface directed by mutagenesis, biophysical analysis, and molecular dynamics simulations. Scientific Reports, 2019, 9, 4482.	1.6	31
241	Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy. Biomaterials, 2019, 207, 1-9.	5.7	118
242	Immunomodulatory roles of nitric oxide in cancer: tumor microenvironment says â€œNOâ€•to antitumor immune response. Translational Research, 2019, 210, 99-108.	2.2	39
243	Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Letters, 2019, 452, 66-70.	3.2	150
244	T-memory cells against cancer: Remembering the enemy. Cellular Immunology, 2019, 338, 27-31.	1.4	16
245	Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy. ACS Nano, 2019, 13, 2936-2947.	7.3	42
246	Prognostic value of ALDH1 and Nestin in advanced cancer: a systematic meta-analysis with trial sequential analysis. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983083.	1.4	16
247	Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. Cancers, 2019, 11, 305.	1.7	51
248	Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?. Frontiers in Immunology, 2019, 10, 9.	2.2	126
249	Synthesis, Characterization for New Nanometric VO(II)â€“Thioacetanilide Complexes by, Spectral, Thermal, Molecular Computations and DNA Interaction Study Beside Promising Antitumor Activity. Journal of Inorganic and Organometallic Polymers and Materials, 2019, 29, 1606-1624.	1.9	25
250	Three-dimensional imaging and quantitative analysis in CLARITY processed breast cancer tissues. Scientific Reports, 2019, 9, 5624.	1.6	45
251	SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints. Leukemia, 2019, 33, 2585-2598.	3.3	29
252	Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis. JAMIA Open, 2019, 2, 173-178.	1.0	29

#	Article	IF	Citations
253	Applications of molecular engineering in Tâ€cellâ€based immunotherapies. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2019, 11, e1557.	3.3	6
254	Enhanced Antitumor Immune Response in 2â€²-5â€² Oligoadenylate Synthetase-Like 1- (OASL1-) Deficient Mice upon Cisplatin Chemotherapy and Radiotherapy. Journal of Immunology Research, 2019, 2019, 1-14.	0.9	3
255	TAMing pancreatic cancer: combat with a double edged sword. Molecular Cancer, 2019, 18, 48.	7.9	61
256	Therapeutic approaches for targeting receptor tyrosine kinase like orphan receptor-1 in cancer cells. Expert Opinion on Therapeutic Targets, 2019, 23, 447-456.	1.5	21
257	Prognostic Value of CD44 and Its Isoforms in Advanced Cancer: A Systematic Meta-Analysis With Trial Sequential Analysis. Frontiers in Oncology, 2019, 9, 39.	1.3	20
258	Phenotype and Function of Activated Natural Killer Cells From Patients With Prostate Cancer: Patient-Dependent Responses to Priming and IL-2 Activation. Frontiers in Immunology, 2018, 9, 3169.	2.2	18
259	Precise tuning of gene expression levels in mammalian cells. Nature Communications, 2019, 10, 818.	5.8	43
260	The Effects of AHCCÂ®, a Standardized Extract of Cultured Lentinura edodes Mycelia, on Natural Killer and T Cells in Health and Disease: Reviews on Human and Animal Studies. Journal of Immunology Research, 2019, 2019, 1-7.	0.9	18
261	Oral adjuvant therapy for colorectal cancer: recent developments and future targets. Therapeutic Delivery, 2019, 10, 659-669.	1.2	4
262	Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy. Frontiers in Medicine, 2019, 6, 262.	1.2	19
263	Recruitment of CD103 ⁺ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy. Science Advances, 2019, 5, eaay1357.	4.7	87
264	Caveolin-2 deficiency induces a rapid anti-tumor immune response prior to regression of implanted murine lung carcinoma tumors. Scientific Reports, 2019, 9, 18970.	1.6	9
265	Immunotherapy â€“ Strategies for Expanding Its Role in the Treatment of All Major Tumor Sites. Cureus, 2019, 11, e5938.	0.2	9
266	Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma. International Journal of Cancer, 2019, 144, 886-896.	2.3	22
267	Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice. Journal of Controlled Release, 2019, 294, 165-175.	4.8	93
268	Non-replicating Newcastle Disease Virus as an adjuvant for DNA vaccine enhances antitumor efficacy through the induction of TRAIL and granzyme B expression. Virus Research, 2019, 261, 72-80.	1.1	13
269	Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting. Current Medical Research and Opinion, 2019, 35, 817-827.	0.9	12
270	Identification of discrepancy between CTLA4 expression and CTLA4 activation in gastric cancer. Immunopharmacology and Immunotoxicology, 2019, 41, 386-393.	1.1	27

#	Article	IF	Citations
271	Biomimetic Nanoparticle Vaccines for Cancer Therapy. Advanced Biology, 2019, 3, e1800219.	3.0	84
272	Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. , 2019, 7, 6.		190
273	Circulating myeloidâ€derived suppressor cells: An independent prognostic factor in patients with breast cancer. Journal of Cellular Physiology, 2019, 234, 3515-3525.	2.0	62
274	Predictive Biomarkers and Targeted Therapies in Immuno-oncology. , 2019, , 335-344.		1
275	A Clickâ€Chemistry Linked 2â€²3â€²â€cGAMP Analogue. Chemistry - A European Journal, 2019, 25, 2089-2095.	1.7	16
276	An in vitro assessment for evaluating the efficiency of Î²â€•d â€mannuronic acid (M2000) in myelodysplastic syndrome. Journal of Cellular Physiology, 2019, 234, 12971-12977.	2.0	5
277	Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma. Expert Opinion on Investigational Drugs, 2019, 28, 39-50.	1.9	7
278	Metal Drugs and the Anticancer Immune Response. Chemical Reviews, 2019, 119, 1519-1624.	23.0	237
279	Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis. Aging Male, 2020, 23, 132-138.	0.9	24
280	Development and validation of an immune prognostic signature for ovarian carcinoma. Cancer Reports, 2020, 3, e1166.	0.6	4
281	ICeD-T Provides Accurate Estimates of Immune Cell Abundance in Tumor Samples by Allowing for Aberrant Gene Expression Patterns. Journal of the American Statistical Association, 2020, 115, 1055-1065.	1.8	18
282	A systems approach to clinical oncology uses deep phenotyping to deliver personalized care. Nature Reviews Clinical Oncology, 2020, 17, 183-194.	12.5	41
283	The impact of corticosteroid use during anti-PD1 treatment. Journal of Oncology Pharmacy Practice, 2020, 26, 814-822.	0.5	44
284	Improving cancer therapy through the nanomaterials-assisted alleviation of hypoxia. Biomaterials, 2020, 228, 119578.	5.7	157
285	CD3D is associated with immune checkpoints and predicts favorable clinical outcome in colon cancer. Immunotherapy, 2020, 12, 25-35.	1.0	31
286	Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy. Nanoscale, 2020, 12, 413-436.	2.8	49
287	Lipid-based phagocytosis nanoenhancer for macrophage immunotherapy. Nanoscale, 2020, 12, 1875-1885.	2.8	24
288	Folateâ€“Goldâ€“Bilirubin Nanoconjugate Induces Apoptotic Death in Multidrug-Resistant Oral Carcinoma Cells. European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45, 285-296.	0.6	20

#	Article	IF	Citations
289	Patterns of immune infiltration in lung adenocarcinoma revealed a prognosis-associated microRNAâ€“mast cells network. Human Cell, 2020, 33, 205-219.	1.2	6
290	A New Tumor-Immunotherapy Regimen based on Impulsive Control Strategy. Biomedical Signal Processing and Control, 2020, 57, 101763.	3.5	4
291	Heat-killed Mycobacterium paragordonae therapy exerts an anti-cancer immune response via enhanced immune cell mediated oncolytic activity in xenograft mice model. Cancer Letters, 2020, 472, 142-150.	3.2	11
292	Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy. , 2020, 207, 107456.		42
293	Panâ€cancer RNAâ€seq data stratifies tumours by some hallmarks of cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 418-430.	1.6	28
294	Validation of the QR1 Antibody for the Evaluation of PD-L1 Expression in Nonâ€“Small Cell Lung Adenocarcinomas. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 23-29.	0.6	6
295	Immunomodulatory Effect of Lactobacillus casei in a Murine Model of Colon Carcinogenesis. Probiotics and Antimicrobial Proteins, 2020, 12, 1012-1024.	1.9	18
296	Synthesis, anticancer and antimicrobial evaluation of new pyridyl and thiazolyl clubbed hydrazone scaffolds. Synthetic Communications, 2020, 50, 243-255.	1.1	6
297	p65/miRâ€23a/CCL22 axis regulated regulatory T cells recruitment in hepatitis B virus positive hepatocellular carcinoma. Cancer Medicine, 2020, 9, 711-723.	1.3	12
298	Promising approaches in cancer immunotherapy. Immunobiology, 2020, 225, 151875.	0.8	49
299	How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers. RMD Open, 2020, 6, e001363.	1.8	8
300	Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma. Frontiers in Immunology, 2020, 11, 2105.	2.2	164
301	Organoid culture system for patient-derived lung metastatic osteosarcoma. Medical Oncology, 2020, 37, 105.	1.2	13
302	Research progress of nanomaterial-mediated photodynamic therapy in tumor treatment. Journal of Nanoparticle Research, 2020, 22, 1.	0.8	6
303	Immune escape: A critical hallmark in solid tumors. Life Sciences, 2020, 258, 118110.	2.0	91
304	Sepsis in the era of data-driven medicine: personalizing risks, diagnoses, treatments and prognoses. Briefings in Bioinformatics, 2020, 21, 1182-1195.	3.2	29
305	Increasing the expression of programmed death ligand 2 (PD-L2) but not 4-1BB ligand in colorectal cancer cells. Molecular Biology Reports, 2020, 47, 5689-5697.	1.0	0
306	QSPâ€IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immunoâ€Oncology Applications. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 484-497.	1.3	34

#	Article	IF	Citations
307	The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors. BMC Cancer, 2020, 20, 1128.	1.1	7
308	Rationally Designed Redox-Active Au(I) N-Heterocyclic Carbene: An Immunogenic Cell Death Inducer. Journal of the American Chemical Society, 2020, 142, 20536-20541.	6.6	59
309	High Expression of Pd-1 in Circulating Cells of Patients With Advanced Colorectal Cancer Receiving Adjuvant Therapy. Technology in Cancer Research and Treatment, 2020, 19, 153303382096944.	0.8	2
310	Proteome Analysis of Human Natural Killer Cell Derived Extracellular Vesicles for Identification of Anticancer Effectors. Molecules, 2020, 25, 5216.	1.7	22
311	Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse. OncoImmunology, 2020, 9, 1841392.	2.1	8
312	Immunoadjuvants for cancer immunotherapy: A review of recent developments. Acta Biomaterialia, 2020, 114, 16-30.	4.1	78
313	Past, Present, and Future of Anticancer Nanomedicine . International Journal of Nanomedicine, 2020, Volume 15, 5719-5743.	3.3	23
314	Deep learning-based image analysis methods for brightfield-acquired multiplex immunohistochemistry images. Diagnostic Pathology, 2020, 15, 100.	0.9	35
315	PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 5337.	1.8	26
316	The Impact of a Ketogenic Dietary Intervention on the Quality of Life of Stage II and III Cancer Patients: A Randomized Controlled Trial in the Caribbean. Nutrition and Cancer, 2021, 73, 1590-1600.	0.9	11
317	Treating Immunologically Cold Tumors by Precise Cancer Photoimmunotherapy with an Extendable Nanoplatform. ACS Applied Materials & Interfaces, 2020, 12, 40002-40012.	4.0	18
318	Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy. Frontiers in Chemistry, 2020, 8, 589959.	1.8	157
319	A novel co-culture assay to assess anti-tumor CD8+ T cell cytotoxicity via luminescence and multicolor flow cytometry. Journal of Immunological Methods, 2020, 487, 112899.	0.6	23
320	The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study. Frontiers in Immunology, 2020, 11, 524968.	2.2	7
321	Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. OncoImmunology, 2020, 9, 1818437.	2.1	20
322	Novel Prognostic Model Based on Immune Signature for Head and Neck Squamous Cell Carcinoma. BioMed Research International, 2020, 2020, 1-9.	0.9	7
323	Beyond CAR T cells: Engineered VÎ³9VÎ´2 T cells to fight solid tumors. Immunological Reviews, 2020, 298, 117-133.	2.8	9
324	Emerging neo adjuvants for harnessing therapeutic potential of M1 tumor associated macrophages (TAM) against solid tumors: Enusage of plasticity. Annals of Translational Medicine, 2020, 8, 1029-1029.	0.7	10

#	Article	IF	Citations
325	Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. British Journal of Ophthalmology, 2021, 105, 1263-1271.	2.1	36
326	PIWIL1 promotes gastric cancer via a piRNA-independent mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22390-22401.	3.3	48
327	Emerging Roles of 1D Vertical Nanostructures in Orchestrating Immune Cell Functions. Advanced Materials, 2020, 32, e2001668.	11.1	45
328	Firstâ€inâ€human phase 1 study of MKâ€1248, an antiâ€"glucocorticoidâ€induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. Cancer, 2020, 126, 4926-4935.	2.0	46
329	Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective. Drug Delivery, 2020, 27, 1248-1262.	2.5	16
330	Tackling Resistance to Cancer Immunotherapy: What Do We Know?. Molecules, 2020, 25, 4096.	1.7	12
331	Externally-Controlled Systems for Immunotherapy: From Bench to Bedside. Frontiers in Immunology, 2020, 11, 2044.	2.2	18
332	Nucleic Acid-Based Approaches for Tumor Therapy. Cells, 2020, 9, 2061.	1.8	40
333	Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications. BMC Medicine, 2020, 18, 275.	2.3	42
334	Biomedical nanomaterials for immunological applications: ongoing research and clinical trials. Nanoscale Advances, 2020, 2, 5046-5089.	2.2	47
335	Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the <scp>l</scp>-Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade. ACS Applied Materials & Interfaces, 2020, 12, 41127-41137.	4.0	19
336	Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy. Cancers, 2020, 12, 3729.	1.7	55
337	An Immunomodulatory Gallotanin-Rich Fraction From Caesalpinia spinosa Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma. Frontiers in Immunology, 2020, 11, 584959.	2.2	21
338	ExoHCR: a sensitive assay to profile PD-L1 level on tumor exosomes for immunotherapeutic prognosis. Biophysics Reports, 2020, 6, 290-298.	0.2	2
339	Natural killer cell-based immunotherapy for acute myeloid leukemia. Journal of Hematology and Oncology, 2020, 13, 167.	6.9	55
340	Identification of prognosis-associated immune genes and exploration of immune cell infiltration in colorectal cancer. Biomarkers in Medicine, 2020, 14, 1353-1369.	0.6	5
341	Principles of Neuropharmacodynamics: As Applied to Neuro-Oncology. , 0, , .		0
342	Advances in therapeutic vaccines for treating human papillomavirusâ€related cervical intraepithelial neoplasia. Journal of Obstetrics and Gynaecology Research, 2020, 46, 989-1006.	0.6	33

#	Article	IF	Citations
343	Liposomes as tunable platform to decipher the antitumor immune response triggered by TLR and NLR agonists. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 348-357.	2.0	6
344	The BiTE (bispecific Tâ€cell engager) platform: Development and future potential of a targeted immunoâ€oncology therapy across tumor types. Cancer, 2020, 126, 3192-3201.	2.0	116
345	Mimetic Heat Shock Protein Mediated Immune Process to Enhance Cancer Immunotherapy. Nano Letters, 2020, 20, 4454-4463.	4.5	58
346	Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. BMC Medical Research Methodology, 2020, 20, 103.	1.4	10
347	B cell depletion in murine lupus using cytotoxic T lymphocytes in vivo: Feasibility and benefit. Cellular Immunology, 2020, 353, 104117.	1.4	0
348	Reversal of the immunosuppressive tumor microenvironment by nanoparticle-based activation of immune-associated cells. Acta Pharmacologica Sinica, 2020, 41, 895-901.	2.8	18
350	Cancer immunotherapy: dawn of the death of cancer?. International Reviews of Immunology, 2020, 39, 205-222.	1.5	5
351	Î²-Galactosidase-Catalyzed Fluorescent Reporter Labeling of Living Cells for Sensitive Detection of Cell Surface Antigens. Bioconjugate Chemistry, 2020, 31, 1740-1744.	1.8	8
352	Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma. International Immunopharmacology, 2020, 86, 106694.	1.7	18
353	Parallel evolution of polymer chemistry and immunology: Integrating mechanistic biology with materials design. Advanced Drug Delivery Reviews, 2020, 156, 65-79.	6.6	15
354	A QSP model of prostate cancer immunotherapy to identify effective combination therapies. Scientific Reports, 2020, 10, 9063.	1.6	26
355	Abscopal effect in radioimmunotherapy. International Immunopharmacology, 2020, 85, 106663.	1.7	77
356	The Relevance of Transcription Factors in Gastric and Colorectal Cancer Stem Cells Identification and Eradication. Frontiers in Cell and Developmental Biology, 2020, 8, 442.	1.8	29
357	Current trends in cancer immunotherapy: a literature-mining analysis. Cancer Immunology, Immunotherapy, 2020, 69, 2425-2439.	2.0	9
358	Development and clinical application of bispecific antibody in the treatment of colorectal cancer. Expert Review of Clinical Immunology, 2020, 16, 689-709.	1.3	5
359	Glycogen Synthase Kinase 3Î² in Cancer Biology and Treatment. Cells, 2020, 9, 1388.	1.8	46
360	Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy. Molecular Oncology, 2020, 14, 1680-1694.	2.1	33
361	Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy. BMC Cancer, 2020, 20, 572.	1.1	25

#	Article	IF	Citations
363	Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Frontiers in Immunology, 2020, 11, 369.	2.2	291
364	Echinococcus multilocularis vesicular fluid induces the expression of immune checkpoint proteins in vitro. Parasite Immunology, 2020, 42, e12711.	0.7	8
365	Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. Cancer Cell, 2020, 37, 354-370.e7.	7.7	34
366	Evaluation of Prognosis in Nasopharyngeal Cancer Using Machine Learning. Technology in Cancer Research and Treatment, 2020, 19, 153303382090982.	0.8	11
367	Augmenting Peptide Flexibility by Inserting Gamma-Aminobutyric Acid (GABA) in Their Sequence. International Journal of Peptide Research and Therapeutics, 2020, 26, 2633-2640.	0.9	4
368	Tumor associated macrophages and â€˜NOâ€™. Biochemical Pharmacology, 2020, 176, 113899.	2.0	28
369	Exploiting antibody biology for the treatment of cancer. Immunotherapy, 2020, 12, 255-267.	1.0	7
370	Unanticipated Myocarditis in a Surgical Patient Treated With Pembrolizumab: A Case Report. A&A Practice, 2020, 14, e01177.	0.2	8
371	Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma. Cancer Letters, 2020, 478, 56-69.	3.2	32
372	Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs). Frontiers in Oncology, 2020, 10, 654.	1.3	52
373	The Contribution of Race to Breast Tumor Microenvironment Composition and Disease Progression. Frontiers in Oncology, 2020, 10, 1022.	1.3	31
374	Tumor microenvironment characterization in head and neck cancer identifies prognostic and immunotherapeutically relevant gene signatures. Scientific Reports, 2020, 10, 11163.	1.6	28
375	How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy. Frontiers in Pharmacology, 2020, 11, 972.	1.6	26
376	Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Cancer Letters, 2020, 490, 12-19.	3.2	10
377	Tumor cell membrane enveloped aluminum phosphate nanoparticles for enhanced cancer vaccination. Journal of Controlled Release, 2020, 326, 297-309.	4.8	66
378	B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncology, 2020, 16, 1767-1791.	1.1	16
379	Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells. Pharmaceutics, 2020, 12, 158.	2.0	63
380	Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine, 2020, 382, 810-821.	13.9	1,542

#	Article	IF	Citations
381	Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan. Expert Review of Molecular Diagnostics, 2020, 20, 601-610.	1.5	2
382	Unleashing Natural Killer Cells in the Tumor Microenvironmentâ€“The Next Generation of Immunotherapy?. Frontiers in Immunology, 2020, 11, 275.	2.2	101
383	The Role of Magnetic Nanoparticles in Cancer Nanotheranostics. Materials, 2020, 13, 266.	1.3	48
384	Tumor Microenvironment Characterization in Glioblastoma Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures. Journal of Molecular Neuroscience, 2020, 70, 738-750.	1.1	6
385	Cancer Immunotherapy: An Effective Tool in Cancer Control and Treatment. Current Cancer Therapy Reviews, 2020, 16, 62-69.	0.2	5
386	Surface engineered gold nanorods: intelligent delivery system for cancer therapy. , 2020, , 85-98.		0
387	Advances in living cell-based anticancer therapeutics. Biomaterials Science, 2020, 8, 2344-2365.	2.6	22
388	Identifying and characterising the impact of excitability in a mathematical model of tumour-immune interactions. Journal of Theoretical Biology, 2020, 501, 110250.	0.8	7
389	High-dimensional immune-profiling in cancer: implications for immunotherapy. , 2020, 8, e000363.		49
390	The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434). Investigational New Drugs, 2021, 39, 152-162.	1.2	7
391	Artificial intelligence and the interplay between tumor and immunity. , 2021, , 211-235.		1
392	Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitorsâ€"is it time for a paradigm shift?. Clinical Rheumatology, 2021, 40, 1687-1695.	1.0	15
393	Chemoimmunotherapy for the treatment of prostate cancer: Insights from mathematical modelling. Applied Mathematical Modelling, 2021, 90, 682-702.	2.2	12
394	Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis. Medical Hypotheses, 2021, 146, 110365.	0.8	24
395	Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity. Cancer Research, 2021, 81, 698-712.	0.4	37
396	Tumour targetable and microenvironment-responsive nanoparticles simultaneously disrupt the PD-1/PD-L1 pathway and MAPK/ERK/JNK pathway for efficient treatment of colorectal cancer. Journal of Drug Targeting, 2021, 29, 454-465.	2.1	6
397	Multi-parametric evolution of conditions leading to cancer invasion in biological systems. Applied Mathematical Modelling, 2021, 90, 46-60.	2.2	3
398	Molybdenum-based hetero-nanocomposites for cancer therapy, diagnosis and biosensing application: Current advancement and future breakthroughs. Journal of Controlled Release, 2021, 330, 257-283.	4.8	45

#	Article	IF	Citations
399	Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 1904-1911.	3.2	28
400	Cancer: An unknown territory; rethinking before going ahead. Genes and Diseases, 2021, 8, 655-661.	1.5	29
401	Nanomaterialâ€mediated platinum drugâ€based combinatorial cancer therapy. View, 2021, 2, 20200030.	2.7	28
402	Macrophages in pancreatic cancer: An immunometabolic perspective. Cancer Letters, 2021, 498, 188-200.	3.2	36
403	Immunoliposomes bearing lymphocyte activation gene 3 fusion protein and <scp>P5</scp> peptide: A novel vaccine for breast cancer. Biotechnology Progress, 2021, 37, e3095.	1.3	12
404	Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer. Expert Opinion on Drug Discovery, 2021, 16, 89-99.	2.5	14
405	Targeted Therapies in Cancer Treatment. , 2021, , 57-78.		1
406	Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2021, 1295, 303-315.	0.8	1
407	The Immune Contexture and Cancer Therapy Aspects of the TIM-3 Checkpoint Pathway. E3S Web of Conferences, 2021, 271, 02021.	0.2	0
408	Role of OX40 and its ligand as costimulatory modulators in cancer immunotherapy. AIMS Molecular Science, 2021, 8, 161-173.	0.3	1
409	Blockade of the checkpoint PD-1 by its ligand PD-L1 and the immuno-oncological drugs pembrolizumab and nivolumab. Physical Chemistry Chemical Physics, 2021, 23, 21207-21217.	1.3	9
410	Antibody recruiting molecules (ARMs): synthetic immunotherapeutics to fight cancer. RSC Chemical Biology, 2021, 2, 713-724.	2.0	13
411	Nanotechnology for Diagnosis, Imaging, and Treatment of Head and Neck Cancer. , 2021, , 63-120.		1
412	Anti-PD-1 therapy activates tumoricidic properties of NKT cells and contributes to the overall deceleration of tumor progression in a model of murine mammary carcinoma. Vojnosanitetski Pregled, 2022, 79, 764-773.	0.1	2
413	The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?. Cancer Immunology, Immunotherapy, 2021, 70, 1797-1809.	2.0	12
414	Structural influence of antibody recruiting glycodendrimers (ARGs) on antitumoral cytotoxicity. Biomaterials Science, 2021, 9, 4076-4085.	2.6	10
415	Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma. Medicine (United States), 2021, 100, e24339.	0.4	7
416	Therapeutic Approaches to Employ Monoclonal Antibody for Cancer Treatment. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 42-88.	0.1	0

#	Article	IF	Citations
417	Drug delivery systems in cancer therapy. , 2021, , 423-454.		2
418	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. Current Oncology Reports, 2021, 23, 13.	1.8	38
420	Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. Scientific Reports, 2021, 11, 4530.	1.6	27
421	Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies. Frontiers in Cardiovascular Medicine, 2021, 8, 619650.	1.1	17
422	The liposome of trehalose dimycolate extracted from M.Âbovis BCG induces antitumor immunity via the activation of dendritic cells and CD8+ T cells. Cancer Immunology, Immunotherapy, 2021, 70, 2529-2543.	2.0	15
423	Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1. ACS Medicinal Chemistry Letters, 2021, 12, 443-450.	1.3	19
424	STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients. Frontiers in Immunology, 2020, 11, 613215.	2.2	13
425	Antitumour metastasis and the antiangiogenic and antitumour effects of a Eimeria stiedae soluble protein. Parasite Immunology, 2021, 43, e12825.	0.7	3
426	Serum CD4 Is Associated with the Infiltration of CD4+T Cells in the Tumor Microenvironment of Gastric Cancer. Journal of Immunology Research, 2021, 2021, 1-13.	0.9	7
427	Construction of in vitro patientâ€derived tumor models to evaluate anticancer agents and cancer immunotherapy. Oncology Letters, 2021, 21, 406.	0.8	7
428	Systemic Immunotherapy with Micellar Resiquimodâ€“Polymer Conjugates Triggers a Robust Antitumor Response in a Breast Cancer Model. Advanced Healthcare Materials, 2021, 10, e2100008.	3.9	15
429	Control Strategies for Carcinogenic-Associated Helminthiases: An Integrated Overview. Frontiers in Cellular and Infection Microbiology, 2021, 11, 626672.	1.8	1
430	Enhancing Cancer Immunotherapy Treatment Goals by Using Nanoparticle Delivery System. International Journal of Nanomedicine, 2021, Volume 16, 2389-2404.	3.3	17
431	Complement in Tumourigenesis and the Response to Cancer Therapy. Cancers, 2021, 13, 1209.	1.7	18
432	Tumor Immunometabolism Characterization in Ovarian Cancer With Prognostic and Therapeutic Implications. Frontiers in Oncology, 2021, 11, 622752.	1.3	9
433	Endocrine toxicity of cancer immunotherapy: clinical challenges. Endocrine Connections, 2021, 10, R116-R124.	0.8	16
434	Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade. Gut, 2022, 71, 521-533.	6.1	108
435	Recent Advances in Nanomaterialâ€Based Nanoplatforms for Chemodynamic Cancer Therapy. Advanced Functional Materials, 2021, 31, 2100243.	7.8	206

#	Article	IF	Citations
436	High drug loading and pH-responsive nanomedicines driven by dynamic boronate covalent chemistry for potent cancer immunotherapy. Nano Research, 2021, 14, 3913-3920.	5.8	11
439	Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review. Cancer Cell International, 2021, 21, 239.	1.8	35
440	The confounding effect of interleukin-6 on apoptosis of MCF-7 cells through down-regulation of MMP-2/-9 mRNA expression. Turkish Journal of Biochemistry, 2021, 46, 549-555.	0.3	7
441	Brain Tumor Vaccines. Neurosurgery Clinics of North America, 2021, 32, 225-234.	0.8	4
442	Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Cancer Cell International, 2021, 21, 196.	1.8	18
443	Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines. Life Sciences, 2021, 271, 119110.	2.0	25
444	Construction and investigation of plasmid-induced effects on growth of GFP-expressing Salmonella strains. Life Sciences Medicine and Biomedicine, 2021, 5, .	0.1	0
445	The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 654877.	2.2	19
446	Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines. Cancer Gene Therapy, 2021, 28, 935-946.	2.2	10
447	Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles. Pharmaceutics, 2021, 13, 525.	2.0	17
448	Functional Impairments and Rehabilitation Outcomes of Patients With Immunotherapy-Induced Acute Inflammatory Demyelinating Polyradiculoneuropathy, Myasthenia Gravis, and Myositis. American Journal of Physical Medicine and Rehabilitation, 2021, 100, 1015-1019.	0.7	1
449	Structure-activity Relationship of Indomethacin Derivatives as IDO1 Inhibitors. Anticancer Research, 2021, 41, 2287-2296.	0.5	2
450	Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Bloodâ€"Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. Clinical Cancer Research, 2021, 27, 3744-3756.	3.2	69
451	Preclinical models and technologies to advance nanovaccine development. Advanced Drug Delivery Reviews, 2021, 172, 148-182.	6.6	18
452	Extracellular Vesicles and Their Current Role in Cancer Immunotherapy. Cancers, 2021, 13, 2280.	1.7	20
453	Informing the new developments and future of cancer immunotherapy. Cancer and Metastasis Reviews, 2021, 40, 549-562.	2.7	17
454	TET2 Inhibits PD-L1 Gene Expression in Breast Cancer Cells through Histone Deacetylation. Cancers, 2021, 13, 2207.	1.7	19
455	Recombinant Human Adenovirus-p53 Therapy for the Treatment of Oral Leukoplakia and Oral Squamous Cell Carcinoma: A Systematic Review. Medicina (Lithuania), 2021, 57, 438.	0.8	3

#	Article	IF	Citations
456	Chemotherapy in focus: A meta-analysis confronts immunotherapy in the treatment of advanced melanoma. Critical Reviews in Oncology/Hematology, 2021, 161, 103304.	2.0	3
457	Nanomaterials to Fight Cancer: An Overview on Their Multifunctional Exploitability. Journal of Nanoscience and Nanotechnology, 2021, 21, 2760-2777.	0.9	0
458	A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. Frontiers in Immunology, 2021, 12, 654463.	2.2	16
459	Biologics and their delivery systems: Trends in myocardial infarction. Advanced Drug Delivery Reviews, 2021, 173, 181-215.	6.6	23
460	B Cell Orchestration of Anti-tumor Immune Responses: A Matter of Cell Localization and Communication. Frontiers in Cell and Developmental Biology, 2021, 9, 678127.	1.8	63
461	Identification of immune cell infiltration pattern and related critical genes in metastatic castration-resistant prostate cancer by bioinformatics analysis. Cancer Biomarkers, 2021, 32, 1-15.	0.8	6
462	Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms. European Journal of Health Economics, 2021, 22, 1301-1309.	1.4	3
463	Precision Medicine in Lung Cancer: Challenges and Opportunities in Diagnostic and Therapeutic Purposes. , 0, , .		0
464	Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma. Molecular Therapy - Oncolytics, 2021, 21, 288-302.	2.0	25
465	PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response. BioMed Research International, 2021, 2021, 1-6.	0.9	2
466	Memory-like Differentiation Enhances NK Cell Responses to Melanoma. Clinical Cancer Research, 2021, 27, 4859-4869.	3.2	33
467	Evaluating the impacts of emerging cancer therapies on ovarian function. Current Opinion in Endocrine and Metabolic Research, 2021, 18, 15-28.	0.6	6
468	Tumor hypoxia-activated combinatorial nanomedicine triggers systemic antitumor immunity to effectively eradicate advanced breast cancer. Biomaterials, 2021, 273, 120847.	5.7	55
469	Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes. Viruses, 2021, 13, 1271.	1.5	30
470	Effects of a Unique Combination of the Whole-Body Low Dose Radiotherapy with Inactivation of Two Immune Checkpoints and/or a Heat Shock Protein on the Transplantable Lung Cancer in Mice. International Journal of Molecular Sciences, 2021, 22, 6309.	1.8	8
471	In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC). Bioorganic Chemistry, 2021, 111, 104833.	2.0	37
472	Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review. Cardio-Oncology, 2021, 7, 26.	0.8	3
473	Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy. Anticancer Research, 2021, 41, 4133-4141.	0.5	4

#	Article	IF	Citations
474	A Review on Metal- and Metal Oxide-Based Nanozymes: Properties, Mechanisms, and Applications. Nano-Micro Letters, 2021, 13, 154.	14.4	221
475	The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer. Drug Discovery Today, 2021, 26, 1721-1727.	3.2	50
476	Positron emission tomography imaging with 89Zr-labeled anti-CD8 cys-diabody reveals CD8+ cell infiltration during oncolytic virus therapy in a glioma murine model. Scientific Reports, 2021, 11, 15384.	1.6	13
477	Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy. Cancer Letters, 2021, 511, 68-76.	3.2	33
478	Identification of a prognostic ferroptosis-related lncRNA signature in the tumor microenvironment of lung adenocarcinoma. Cell Death Discovery, 2021, 7, 190.	2.0	68
479	Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis. Oncogenesis, 2021, 10, 48.	2.1	10
480	Characteristics and Clinical Application of Extracellular Vesicle-Derived DNA. Cancers, 2021, 13, 3827.	1.7	22
481	A review on the advances and challenges of immunotherapy for head and neck cancer. Cancer Cell International, 2021, 21, 406.	1.8	30
482	Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domain. Scientific Reports, 2021, 11, 15467.	1.6	4
483	A regulatory loop among CD276, miR-29c-3p, and Myc exists in cancer cells against natural killer cell cytotoxicity. Life Sciences, 2021, 277, 119438.	2.0	9
484	The era of gene therapy: From preclinical development to clinical application. Drug Discovery Today, 2021, 26, 1602-1619.	3.2	26
485	Combined use of cisplatin plus natural killer cells overcomes immunoresistance of cisplatin resistant ovarian cancer. Biochemical and Biophysical Research Communications, 2021, 563, 40-46.	1.0	7
486	Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies. Vaccines, 2021, 9, 724.	2.1	27
487	Opportunities and Challenges for Gut Microbiota in Acute Leukemia. Frontiers in Oncology, 2021, 11, 692951.	1.3	7
488	Autoimmune Responses in Oncology: Causes and Significance. International Journal of Molecular Sciences, 2021, 22, 8030.	1.8	12
489	MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model. Scientific Reports, 2021, 11, 15648.	1.6	19
490	Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer. Frontiers in Oncology, 2021, 11, 712807.	1.3	12
491	Immune-Related Genes Are Prognostic Markers for Prostate Cancer Recurrence. Frontiers in Genetics, 2021, 12, 639642.	1.1	11

#	Article	IF	Citations
492	CpG-Based Nanovaccines for Cancer Immunotherapy. International Journal of Nanomedicine, 2021, Volume 16, 5281-5299.	3.3	38
493	Response to Immune Checkpoint Inhibitor Treatment in Advanced Cervical Cancer and Biomarker Study. Frontiers in Medicine, 2021, 8, 669587.	1.2	8
494	A Novel Signature Constructed by Immune-Related LncRNA Predicts the Immune Landscape of Colorectal Cancer. Frontiers in Genetics, 2021, 12, 695130.	1.1	8
495	Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series. Beyond Rheumatology, 2021, 3, .	0.3	1
496	Step-by-Step Immune Activation for Suicide Gene Therapy Reinforcement. International Journal of Molecular Sciences, 2021, 22, 9376.	1.8	5
497	A structural perspective on the design of decoy immune modulators. Pharmacological Research, 2021, 170, 105735.	3.1	0
498	The Optimal Second-Line Systemic Treatment Model for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis. Frontiers in Immunology, 2021, 12, 719650.	2.2	3
499	PCSK9 and cancer: Rethinking the link. Biomedicine and Pharmacotherapy, 2021, 140, 111758.	2.5	41
500	YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma. Frontiers in Pharmacology, 2021, 12, 709548.	1.6	21
501	Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review. Dermatology and Therapy, 2021, 11, 1481-1496.	1.4	12
502	Cancer and immunotherapy: a role for microbiota composition. European Journal of Cancer, 2021, 155, 145-154.	1.3	15
503	Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin. Cancers, 2021, 13, 4566.	1.7	10
504	Interventional Strategies in Cancer-induced Cardiovascular Disease. Current Oncology Reports, 2021, 23, 133.	1.8	2
505	Personalized Nanovaccine Coated with Calcinetin-Expressed Cancer Cell Membrane Antigen for Cancer Immunotherapy. Nano Letters, 2021, 21, 8418-8425.	4.5	55
506	SPENCER: a comprehensive database for small peptides encoded by noncoding RNAs in cancer patients. Nucleic Acids Research, 2022, 50, D1373-D1381.	6.5	17
507	Chimeric Antigen Receptor T-Cell Therapy: An Overview of the Changing Face of Cancer Immunotherapy. Trends in Medical Sciences, 2021, 2, .	0.1	0
508	Dual Responsive Hybrid Nanoparticle for Tumor Chemotherapy Combined with Photothermal Therapy. Journal of Pharmaceutical Sciences, 2021, 110, 3851-3861.	1.6	5
509	Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy. Cureus, 2021, 13, e17992.	0.2	1

#	Article	IF	Citations
510	Engineered in vitro tumor models for cell-based immunotherapy. Acta Biomaterialia, 2021, 132, 345-359.	4.1	13
511	Immune Cycleâ€Based Strategies for Cancer Immunotherapy. Advanced Functional Materials, 2021, 31, 2107540.	7.8	24
512	Bacteria-based immune therapies for cancer treatment. Seminars in Cancer Biology, 2022, 86, 1163-1178.	4.3	10
513	Polysaccharide-based nanomedicines for cancer immunotherapy: A review. Bioactive Materials, 2021, 6, 3358-3382.	8.6	74
514	Dynamic nanoassemblies of nanomaterials for cancer photomedicine. Advanced Drug Delivery Reviews, 2021, 177, 113954.	6.6	35
515	Chimeric antigen receptor T-cell therapy: An emergency medicine focused review. American Journal of Emergency Medicine, 2021, 50, 369-375.	0.7	2
516	Immune checkpoint inhibitors: An emergency medicine focused review. American Journal of Emergency Medicine, 2021, 50, 335-344.	0.7	5
517	Integrating metabolic engineering and immunotherapy. Current Opinion in Systems Biology, 2021, 28, 100361.	1.3	2
518	Futuristic approach to cancer treatment. Gene, 2021, 805, 145906.	1.0	17
519	Image-guided cancer immunotherapy. , 2022, , 427-467.		0
520	Innate and adaptive immunity in cancer. , 2022, , 19-61.		0
521	Polymeric scaffolds for antitumor immune cell priming. , 2022, , 63-95.		2
522	Engineering approaches for studying immune-tumor cell interactions and immunotherapy. IScience, 2021, 24, 101985.	1.9	52
523	A mathematical model for the quantification of a patientâ€™s sensitivity to checkpoint inhibitors and long-term tumour burden. Nature Biomedical Engineering, 2021, 5, 297-308.	11.6	28
524	Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199298.	1.4	16
525	Ultrasensitive detection of programmed death-ligand 1 (PD-L1) in whole blood using dispersible electrodes. Chemical Communications, 2021, 57, 2559-2562.	2.2	13
526	Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages. Nanoscale, 2021, 13, 4705-4727.	2.8	33
527	Molecular Diversity of Plasma Membrane Ca2+ Transporting ATPases: Their Function Under Normal and Pathological Conditions. Advances in Experimental Medicine and Biology, 2020, 1131, 93-129.	0.8	17

#	Article	IF	Citations
528	Superparamagnetic Iron Oxide Nanoparticles for Cancer Theranostic Applications. , 2019, , 245-276.		14
529	Tumor-Associated Myeloid Cells in Cancer Progression. , 2020, , 29-46.		1
530	Targeting the Tumor-Associated Macrophages for â€˜Normalizingâ€™ Cancer. Human Perspectives in Health Sciences and Technology, 2020, , 245-274.	0.2	2
531	Immune-Related Adverse Events: Pneumonitis. Advances in Experimental Medicine and Biology, 2020, 1244, 255-269.	0.8	38
532	Hereditary Colorectal Cancer: Immunotherapy Approaches. , 2018, , 385-399.		1
533	New Emerging Molecules in Cancer Research Which Hold Promise in Current Era. , 2019, , 539-583.		1
534	Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy. Advances in Therapy, 2020, 37, 3178-3184.	1.3	27
535	Investigation of immune cell markers in feline oral squamous cell carcinoma. Veterinary Immunology and Immunopathology, 2018, 202, 52-62.	0.5	18
536	Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. JNCI Cancer Spectrum, 2021, 5, pkaa115.	1.4	14
537	Immune Checkpoint Inhibitorâ€“Induced Ptosis in a Patient With Prostate Cancer. Journal of Neuro-Ophthalmology, 2021, 41, e71-e72.	0.4	3
540	Cancer Immunotherapy: An Evidence-Based Overview and Implications for Practice. Clinical Journal of Oncology Nursing, 2017, 21, 13-21.	0.3	21
541	Immunotherapy: Exploring the State of the Science. Clinical Journal of Oncology Nursing, 2017, 21, 9-12.	0.3	4
542	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. F1000Research, 2020, 9, 337.	0.8	6
543	An Interaction-based Approach for Affinity Prediction between Antigen Peptide and Human Leukocyte Antigen Using COMBINE Analysis. Chem-Bio Informatics Journal, 2017, 17, 93-102.	0.1	2
544	In vitro immunotherapy potency assays using real-time cell analysis. PLoS ONE, 2018, 13, e0193498.	1.1	76
545	Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia. Endocrine-Related Cancer, 2019, 26, 293-301.	1.6	62
546	Cancer Immunotherapy and Immunonutrition. MOJ Anatomy & Physiology, 2017, 3, .	0.2	1
547	Immune gene signature delineates a subclass of thyroid cancer with unfavorable clinical outcomes. Aging, 2020, 12, 5733-5750.	1.4	4

#	Article	IF	Citations
548	Zinc oxide nanoparticles (ZnO NPs) combined with cisplatin and gemcitabine inhibits tumor activity of NSCLC cells. Aging, 2020, 12, 25767-25777.	1.4	21
549	Immunotherapy of WAP-TNP mice with early stage mammary gland tumors. Oncotarget, 2017, 8, 67790-67804.	0.8	1
550	3D-cultivation of NSCLC cell lines induce gene expression alterations of key cancer-associated pathways and mimicin-vivoconditions. Oncotarget, 2017, 8, 112647-112661.	0.8	13
551	Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting. Oncotarget, 2018, 9, 3576-3589.	0.8	19
552	Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget, 2018, 9, 8972-8984.	0.8	3
553	Low-frequency HIFU induced cancer immunotherapy: tempting challenges and potential opportunities. Cancer Biology and Medicine, 2019, 16, 714-728.	1.4	20
554	Future perspectives in cancer immunotherapy. Annals of Translational Medicine, 2016, 4, 273-273.	0.7	29
555	Endpoint surrogacy in oncological randomized controlled trials with immunotherapies: a systematic review of trial-level and arm-level meta-analyses. Annals of Translational Medicine, 2019, 7, 244-244.	0.7	17
556	Role of Nuclear Factor Erythroid 2-Related Factor 2 (NRF-2) Mediated Antioxidant Response on the Synergistic Antitumor Effect of L-Arginine and 5-Fluro Uracil (5FU) in Breast Adenocarcinoma. Current Pharmaceutical Design, 2019, 25, 1643-1652.	0.9	8
557	Nanoparticles: Properties and Applications in Cancer Immunotherapy. Current Pharmaceutical Design, 2019, 25, 1962-1979.	0.9	12
558	Therapeutic Potential of Targeting Transforming Growth Factor-beta in Colorectal Cancer: Rational and Progress. Current Pharmaceutical Design, 2019, 25, 4085-4089.	0.9	13
559	Integrating Bioinformatics Strategies in Cancer Immunotherapy: Current and Future Perspectives. Combinatorial Chemistry and High Throughput Screening, 2020, 23, 687-698.	0.6	7
560	ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies. Current Drug Delivery, 2020, 17, 23-51.	0.8	16
561	Overview of Current Immunotherapies Targeting Mutated KRAS Cancers. Current Topics in Medicinal Chemistry, 2019, 19, 2158-2175.	1.0	4
562	Towards Breast Cancer Vaccines, Progress and Challenges. Current Drug Discovery Technologies, 2019, 16, 251-258.	0.6	21
563	Optimization of a Density Gradient Centrifugation Protocol for Isolation of Peripheral Blood Mononuclear Cells. Acta Marisiensis - Seria Medica, 2018, 64, 83-90.	0.3	7
564	Genetically engineered CAR T-immune cells for cancer therapy: recent clinical developments, challenges, and future directions. Journal of Applied Biomedicine, 2019, 17, 11-11.	0.6	5
565	Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma. Frontiers in Veterinary Science, 2021, 8, 621758.	0.9	6

#	Article	IF	Citations
566	An overview of the tumor microenvironment, from cells to complex networks (Review). Experimental and Therapeutic Medicine, 2020, 21, 96.	0.8	40
567	MUC1 Antigen-Specific CD8 T Lymphocytes Targeting MCF7 and MDA-MB-231 Human Breast Adenocarcinoma Cell Lines. Journal of Cancer Therapy, 2019, 10, 495-509.	0.1	5
569	Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma. Clinical Medicine, 2020, 20, 163-168.	0.8	21
570	Nucleic Acid Drugsâ€"Current Status, Issues, and Expectations for Exosomes. Cancers, 2021, 13, 5002.	1.7	42
571	Tumor microenvironment-responsive dynamic inorganic nanoassemblies for cancer imaging and treatment. Advanced Drug Delivery Reviews, 2021, 179, 114004.	6.6	55
572	Pulmonary adverse events due to immune checkpoint inhibitors: A literature review. Monaldi Archives for Chest Disease, 2021, , .	0.3	0
573	The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review. International Immunopharmacology, 2021, 101, 108220.	1.7	6
574	The Future of Checkpoint Blockade to Treat Cancer Patients. Journal of Cancer Prevention & Current Research, 2016, 6, .	0.1	0
575	Personalized Therapeutics: First Take Home Messages. , 2017, , 11-23.		0
576	Selection and Evaluation of Human Recombinant Antibodies against ErbB2 Antigen for Breast Cancer Immunotherapy. Shiraz E Medical Journal, 2017, 18, .	0.1	0
577	REVIEW OF APPROACHES TO IMMUNOTHERAPY IN ONCOLOGY. IssledovaniÃ¢ I Praktika V Medicine, 2017, 4, 51-65.	0.1	4
578	Topotecan Decreases the Expression of Programmed Death-Ligand 1 in Glioblastoma Cell Lines; Implications for Immunotherapy. Matters, 0, , .	1.0	3
579	Single Nucleotide Polymorphisms of Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) and Susceptibility to Chronic Viral Hepatitis B and C Infections. Journal of Renal and Hepatic Disorders, 2018, 2, 10-17.	0.1	2
583	A contribution to the mathematical modeling of immune-cancer competition. Communications in Applied and Industrial Mathematics, 2018, 9, 76-90.	0.6	2
584	Gastrointestinal Lymphomas. , 2019, , 960-969.		0
585	Emerging Immune Context. , 2019, , 269-329.		0
586	Identifying the most effective hydatid cyst fluid fraction for anticancer vaccination of 4T1 breast tumor-bearing mice. International Journal of Preventive Medicine, 2019, 10, 143.	0.2	3
587	Induction of Apoptosis Scutellaria baicalensis Georgi Root Extract by Inactivation of the Phosphatidyl Inositol 3-kinase/Akt Signaling Pathway in Human Leukemia U937 Cells. Journal of Cancer Prevention, 2019, 24, 11-19.	0.8	2

#	Article	IF	Citations
588	Strategies of current cancer immunotherapy. Postepy Higieny I Medycyny Doswiadczalnej, 2019, 73, 898-908.	0.1	0
589	Enhancement of specific T-lymphocyte responses by monocyte-derived dendritic cells pulsed with E2 protein of human papillomavirus 16 and human p16INK4A. PeerJ, 2020, 8, e9213.	0.9	2
591	Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications. Frontiers in Oncology, 2021, 11, 770561.	1.3	51
592	The replicative CMG helicase: the ideal target for cancer therapy. Ukrainian Biochemical Journal, 2020, 92, 53-62.	0.1	0
593	The New Era of Immunotherapy in Bile Duct Cancer Management. , 0, , .		0
594	Theoretical premises of a â€œthree in oneâ€•therapeutic approach to treat immunogenic and nonimmunogenic cancers: a narrative review. Translational Cancer Research, 2021, 10, 4958-4972.	0.4	3
595	Cancer Molecular and Functional Imaging. , 2020, , 729-738.		0
597	The role of Globo H and SSEA-4 in the development and progression of cancer, and their potential as therapeutic targets. Future Oncology, 2022, 18, 117-134.	1.1	9
598	Tumor Marker B7-H6 Bound to the Coiled Coil Peptide-Polymer Conjugate Enables Targeted Therapy by Activating Human Natural Killer Cells. Biomedicines, 2021, 9, 1597.	1.4	2
599	Equipping Cancer Cell Membrane Vesicles with Functional DNA as a Targeted Vaccine for Cancer Immunotherapy. Nano Letters, 2021, 21, 9410-9418.	4.5	39
600	Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models. American Journal of Cancer Research, 2019, 9, 53-63.	1.4	19
601	Temozolomide promotes immune escape of GBM cells via upregulating PD-L1. American Journal of Cancer Research, 2019, 9, 1161-1171.	1.4	19
602	Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response. BMJ Case Reports, 2020, 13, .	0.2	2
603	Prognostic impact of sarcopenia on immune-related adverse events in malignancies received immune checkpoint inhibitors: a systematic review and meta-analysis. Translational Cancer Research, 2021, 10, 5150-5158.	0.4	6
604	Chemokine Pathways in Cutaneous Melanoma: Their Modulation by Cancer and Exploitation by the Clinician. Cancers, 2021, 13, 5625.	1.7	8
605	Anti-Tumor Necrosis Factor Receptor 2 Antibody Combined With Anti-PD-L1 Therapy Exerts Robust Antitumor Effects in Breast Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 720472.	1.8	4
606	Pulmonary Toxicities of Immunotherapy. Advances in Experimental Medicine and Biology, 2021, 1342, 357-375.	0.8	4
607	Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy. Pharmaceutics, 2022, 14, 120.	2.0	28

#	Article	IF	Citations
608	Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. Theranostics, 2022, 12, 1030-1060.	4.6	49
609	Up-converted nano-gasholder with precise nitric oxide release remodels immunosuppressive microenvironment and potentiates tumor immunotherapy. Nano Today, 2022, 42, 101381.	6.2	10
610	PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2022, 43, 103324.	0.6	8
611	Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors. Molecular Therapy - Oncolytics, 2022, 24, 194-204.	2.0	7
612	Prognostic value of immune-related genes in laryngeal squamous cell carcinoma. Translational Cancer Research, 2020, 9, 6287-6302.	0.4	2
613	Brain-derived neurotrophic factor and inflammation in depression: Pathogenic partners in crime?. World Journal of Psychiatry, 2022, 12, 77-97.	1.3	46
614	Anticancer Activity of Urease Mimetic Cobalt (III) Complexes on A549-Lung Cancer Cells: Targeting the Acidic Microenvironment. Pharmaceutics, 2022, 14, 211.	2.0	3
615	Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?. Cancers, 2022, 14, 644.	1.7	11
616	Complement System: An Immunotherapy Target in Colorectal Cancer. Frontiers in Immunology, 2022, 13, 810993.	2.2	16
617	OUP accepted manuscript. Stem Cells Translational Medicine, 2022, 11, 239-247.	1.6	8
618	Facile discovery of a therapeutic agent for NK-mediated synergistic antitumor effects using a patient-derived 3D platform. Biomaterials Science, 2022, 10, 678-691.	2.6	2
619	Nanozyme-Based Enhanced Cancer Immunotherapy. Tissue Engineering and Regenerative Medicine, 2022, 19, 237-252.	1.6	24
620	Hormone therapy for cancer treatment. , 2022, , 247-256.		0
621	Nanovaccines with cell-derived components for cancer immunotherapy. Advanced Drug Delivery Reviews, 2022, 182, 114107.	6.6	41
622	Manganese-phenolic nanoadjuvant combines sonodynamic therapy with cGAS-STING activation for enhanced cancer immunotherapy. Nano Today, 2022, 43, 101405.	6.2	86
623	Doxorubicin sensitizes breast cancer cells to natural killerÂcells in connection with increased Fas receptors. International Journal of Molecular Medicine, 2022, 49, .	1.8	7
624	Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment. Frontiers in Oncology, 2022, 12, 809304.	1.3	23
625	Hydrophilic Gold Nanoparticles as Antiâ€PDâ€L1 Antibody Carriers: Synthesis and Interface Properties. Particle and Particle Systems Characterization, 0, , 2100282.	1.2	10

#	Article	IF	Citations
626	The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. Clinical Science, 2022, 136, 197-222.	1.8	86
627	Behandlung rheumatischer immunbedingter Nebenwirkungen bei der Krebsimmuntherapie mit Immun-Checkpoint-Inhibitoren â€“ ist es Zeit fÃ¼r einen Paradigmenwechsel?. Karger Kompass Autoimmun, 0, , 1-8.	0.0	0
628	Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men. Oncology and Therapy, 2022, 10, 185-193.	1.0	1
629	Advances in carbon nanomaterials for immunotherapy. Applied Materials Today, 2022, 27, 101397.	2.3	15
630	Tissueâ€derived extracellular vesicles in cancers and nonâ€cancer diseases: Present and future. Journal of Extracellular Vesicles, 2021, 10, e12175.	5.5	76
631	Adsorption of Lysozyme and Antibodies at Material Surfaces: Implications to Material Compatibility for Development of Biologics. SSRN Electronic Journal, 0, , .	0.4	0
632	Natural killer cell-based strategies for immunotherapy of cancer. Advances in Protein Chemistry and Structural Biology, 2022, 129, 91-133.	1.0	6
633	A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities. International Journal of Technology Assessment in Health Care, 2022, 38, e28.	0.2	3
634	Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy. Frontiers in Oncology, 2022, 12, 847350.	1.3	6
635	Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review. Advances in Cancer Biology Metastasis, 2022, 4, 100035.	1.1	7
636	An Oxidative Stress-Related Genes Signature for Predicting Survival in Bladder Cancer: Based on TCGA Database and Bioinformatics. International Journal of General Medicine, 2022, Volume 15, 2645-2667.	0.8	9
637	Exploration of Novel Pathways Underlying Irreversible Electroporation Induced Anti-Tumor Immunity in Pancreatic Cancer. Frontiers in Oncology, 2022, 12, 853779.	1.3	6
638	Genesis and Mechanism of Some Cancer Types and an Overview on the Role of Diet and Nutrition in Cancer Prevention. Molecules, 2022, 27, 1794.	1.7	24
639	Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. Frontiers in Oncology, 2022, 12, 821903.	1.3	2
640	Discovery of Novel HPK1 Inhibitors Through Structure-Based Virtual Screening. Frontiers in Pharmacology, 2022, 13, 850855.	1.6	5
641	Toxicity and Local Irritation Action of the Biomedical Cell Product Anti-HER2-CAR-T-NK Upon Multiply Repeated Administration. Pharmaceutical Chemistry Journal, 2022, 55, 1276-1281.	0.3	1
642	Kanser immÃ¼noterapisinde gÃ¼ncel yaklaÅŸÄ±mlar ve immÃ¼noterapinin sÄ±nÄ±rlayÄ±cÄ± etkilerine genel bakÄ±ÅŸ. Turkish Journal of Clinics and Laboratory, 0, , .	0.2	0
643	Precision design of engineered nanomaterials to guide immune systems for disease treatment. Matter, 2022, 5, 1162-1191.	5.0	11

#	Article	IF	Citations
644	Cross-kingdom expression of synthetic genetic elements promotes discovery of metabolites in the human microbiome. Cell, 2022, 185, 1487-1505.e14.	13.5	17
645	Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer. ESMO Open, 2022, 7, 100445.	2.0	26
646	PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells. OncoImmunology, 2022, 11, 2054305.	2.1	18
647	Coagulation and inflammation in cancer: Limitations and prospects for treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188727.	3.3	9
648	Photothermal therapy-mediated autophagy in breast cancer treatment: Progress and trends. Life Sciences, 2022, 298, 120499.	2.0	26
649	Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response. Translational Oncology, 2022, 20, 101405.	1.7	25
650	GammaTileÂ® brachytherapy in the treatment of recurrent glioblastomas. Neuro-Oncology Advances, 2022, 4, vdab185.	0.4	10
651	Identification of Novel Biomarkers for Predicting Prognosis and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma Based on ceRNA Network and Immune Infiltration Analysis. BioMed Research International, 2021, 2021, 1-42.	0.9	9
653	External Validation of the Prognostic Value of an Immune-Associated Gene Panel for Clear Cell Renal Cell Carcinomas. Frontiers in Cell and Developmental Biology, 2021, 9, 794840.	1.8	2
654	TIPE2 Promotes Tumor Initiation But Inhibits Tumor Progression in Murine Colitis-Associated Colon Cancer. Inflammatory Bowel Diseases, 2022, 28, 764-774.	0.9	2
655	AHCCÂ®, a Standardized Extract of Cultured Lentinula Edodes Mycelia, Promotes the Anti-Tumor Effect of Dual Immune Checkpoint Blockade Effect in Murine Colon Cancer. Frontiers in Immunology, 2022, 13, 875872.	2.2	5
656	FLG Gene Mutation Up-regulates the Abnormal Tumor Immune Response and Promotes the Progression of Prostate Cancer. Current Pharmaceutical Biotechnology, 2022, 23, 1658-1670.	0.9	8
685	Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response. BMJ Case Reports, 2020, 13, e236242.	0.2	5
686	New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy. Current Research in Pharmacology and Drug Discovery, 2022, 3, 100103.	1.7	12
687	Immunomodulation by Gut Microbiome on Gastrointestinal Cancers: Focusing on Colorectal Cancer. Cancers, 2022, 14, 2140.	1.7	11
688	Heptamethine Cyanine-Loaded Nanomaterials for Cancer Immuno-Photothermal/Photodynamic Therapy: A Review. Pharmaceutics, 2022, 14, 1015.	2.0	12
689	Study on biomimetic nano tumor targeted delivery system for chemotherapy-laser immunotherapy. European Journal of Pharmaceutics and Biopharmaceutics, 2022, , .	2.0	2
690	Adsorption of lysozyme and antibodies at material surfaces: Implications to material compatibility for development of biologics. Journal of Drug Delivery Science and Technology, 2022, , 103416.	1.4	0

#	Article	IF	Citations
691	Nearâ€Infraredâ€Empowered Nanomotorâ€Mediated Targeted Chemotherapy and Mitochondrial Phototherapy to Boost Systematic Antitumor Immunity. Advanced Healthcare Materials, 2022, 11, e2200255.	3.9	17
692	Role of CD68 in tumor immunity and prognosis prediction in pan-cancer. Scientific Reports, 2022, 12, 7844.	1.6	22
693	An in silico Model of T Cell Infiltration Dynamics Based on an Advanced in vitro System to Enhance Preclinical Decision Making in Cancer Immunotherapy. Frontiers in Pharmacology, 2022, 13, 837261.	1.6	6
694	Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC. Journal of Thoracic Oncology, 2022, 17, 909-920.	0.5	28
695	Advances in Nanotechnology-Based Immunotherapy for Glioblastoma. Frontiers in Immunology, 2022, 13, .	2.2	6
696	Full spectrum flow cytometry and mass cytometry: A 32â€marker panel comparison. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2022, 101, 942-959.	1.1	18
697	Universal antigen encoding of T cell activation from high-dimensional cytokine dynamics. Science, 2022, 376, 880-884.	6.0	29
698	Development of a Novel Immune-Related Gene Prognostic Index for Breast Cancer. Frontiers in Immunology, 2022, 13, 845093.	2.2	12
699	Naringenin and cryptotanshinone shiftÂthe immune response towards Th1 and modulate T regulatory cells via JAK2/STAT3 pathway in breast cancer. BMC Complementary Medicine and Therapies, 2022, 22, .	1.2	6
700	Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy. Expert Opinion on Drug Delivery, 2022, 19, 641-652.	2.4	4
701	Bone Microenvironment-Suppressed T Cells Increase Osteoclast Formation and Osteolytic Bone Metastases in Mice. Journal of Bone and Mineral Research, 2020, 37, 1446-1463.	3.1	11
702	A Brief Introduction to Current Cancer Gene Therapy. Methods in Molecular Biology, 2022, , 1-21.	0.4	3
704	Tracing New Landscapes in the Arena of Nanoparticle-Based Cancer Immunotherapy. Frontiers in Nanotechnology, 0, 4, .	2.4	3
705	Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives. Frontiers in Immunology, 0, 13, .	2.2	3
706	Streptomyces coeruleorubidus as a potential biocontrol agent for Newcastle disease virus. BMC Veterinary Research, 2022, 18, .	0.7	6
707	KDELR1 Is an Independent Prognostic Predictor and Correlates With Immunity in Glioma. Frontiers in Oncology, 0, 12, .	1.3	2
708	<scp>Antibodyâ€Dependent Cellâ€Mediated</scp> Cytotoxicity (<scp>ADCC</scp>) Using T Cells With <scp>NKâ€Like</scp> Phenotype (<scp>Tâ€NK</scp> Cells) in Combination With Avelumab, an <scp>Antiâ€PDâ€L1</scp> Antibody. Immunology, 0, , .	2.0	0
709	Immune Cell Networks Uncover Candidate Biomarkers of Melanoma Immunotherapy Response. Journal of Personalized Medicine, 2022, 12, 958.	1.1	0

#	Article	IF	Citations
711	Circ_0110940 Exerts an Antiapoptotic and Pro-Proliferative Effect in Gastric Cancer Cells via the miR-1178-3p/SLC38A6 Axis. Journal of Oncology, 2022, 2022, 1-12.	0.6	4
712	Research progress on immunotherapy in tripleâ€'negative breast cancer (Review). International Journal of Oncology, 2022, 61, .	1.4	9
713	Establishment and validation of analytical methods for 15 hazardous drugs by UPLC-Q/Orbitrap-HRMS. Annals of Translational Medicine, 2022, 10, 686-686.	0.7	2
714	Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients. Veterinary Sciences, 2022, 9, 327.	0.6	5
715	Dual-responsive nanovaccine for cytosolic delivery of antigens to boost cellular immune responses and cancer immunotherapy. Asian Journal of Pharmaceutical Sciences, 2022, 17, 583-595.	4.3	10
716	The role of neurologists in the era of cancer immunotherapy: Focus on CAR T-cell therapy and immune checkpoint inhibitors. Frontiers in Neurology, 0, 13, .	1.1	9
717	Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ TÂcells. Cell Metabolism, 2022, 34, 1137-1150.e6.	7.2	78
718	Translating MSC Therapy in the Age of Obesity. Frontiers in Immunology, 0, 13, .	2.2	12
719	Clinical safety and efficacy of bispecific antibody in the treatment of solid tumors: A protocol for a systematic review. PLoS ONE, 2022, 17, e0271506.	1.1	1
720	Combined immunotherapeutic effect of Leishmania-derived recombinant aldolase and Ambisome against experimental visceral leishmaniasis. Journal of Microbiology, Immunology and Infection, 2023, 56, 163-171.	1.5	2
724	Cancer cell membrane cloaked nanocarriers: A biomimetic approach towards cancer theranostics. Materials Today Communications, 2022, 33, 104289.	0.9	2
725	Systematic review on PDL-1 exression in human cancer. Indian Journal of Pathology and Oncology, 2022, 9, 298-300.	0.1	0
726	OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer. Cancers, 2022, 14, 3967.	1.7	10
727	Cancer Immunotherapy and Delivery System: An Update. Pharmaceutics, 2022, 14, 1630.	2.0	12
728	The effect of aromatase inhibitors against possible testis toxicity in pembrolizumab treated rats. Andrologia, 2022, 54, .	1.0	1
729	Temsirolimus Enhances Anti-Cancer Immunity by Inducing Autophagy-Mediated Degradation of the Secretion of Small Extracellular Vesicle PD-L1. Cancers, 2022, 14, 4081.	1.7	8
730	Immunotherapeutic targets in nonâ€ssmall cell lung cancer. Immunology, 2023, 168, 256-272.	2.0	5
731	Emerging Vaccine Immunotherapy In NSCLC: The Adverse Reactions of Recent Clinical Trials and Future Directions. , 0, 8, 94-99.		0

#	Article	IF	Citations
732	Use of heparin to rescue immunosuppressive monocyte reprogramming by glioblastoma-derived extracellular vesicles. Journal of Neurosurgery, 2022, , 1-11.	0.9	1
733	Trichopsistides A and B: Two Highly Oxygenated Pentacyclic Polyketides with Promising Inhibitory Effects on the NF-ÎºB Signaling Pathway from the Fungus Trichoderma koningiopsis WZ-196. Journal of Organic Chemistry, 2022, 87, 14058-14067.	1.7	6
734	Background: Immunology and Cancer. Current Clinical Pathology, 2022, , 1-4.	0.0	0
735	Hypochlorous acid-activated two-photon fluorescent probe for evaluation of anticancer drugs-induced cardiotoxicity and screening of antioxidant drugs. Organic Chemistry Frontiers, 0, , .	2.3	0
736	Bioinformatics analysis on differentially expressed genes between colorectal adenoma and colorectal adenocarcinoma. Scottish Medical Journal, 0, , 003693302211223.	0.7	1
737	Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy. , 2022, 10, e005068.		6
739	Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer. The Cochrane Library, 2022, 2022, .	1.5	0
740	Pan-Cancer Analysis and Experimental Validation Identify ACOT7 as a Novel Oncogene and Potential Therapeutic Target in Lung Adenocarcinoma. Cancers, 2022, 14, 4522.	1.7	1
741	Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies. OncoImmunology, 2022, 11, .	2.1	6
742	The heterogeneity of oxidized lipids in individual tumor cells reveals NK cell-mediated cytotoxicity by label-free mass cytometry. Analyst, The, 2022, 147, 5754-5763.	1.7	1
743	Combined Therapy for the Treatment of Cancer. , 2022, , 27-55.		0
744	A Redox-responsive Prodrug Nanogel of TLR7/8 Agonist for Improved Cancer Immunotherapy. Chinese Journal of Polymer Science (English Edition), 2023, 41, 32-39.	2.0	2
745	Preoperative Systemic Therapy for Breast Cancer. Surgical Clinics of North America, 2023, 103, 201-217.	0.5	4
746	Chemobrain, Olfactory and Lifestyle Assessment in Onco-Geriatrics: Sex-Mediated Differences between Chemotherapy and Immunotherapy. Brain Sciences, 2022, 12, 1390.	1.1	2
747	Identification of RUNX1 and IFNGR2 as prognostic-related biomarkers correlated with immune infiltration and subtype differentiation of low-grade glioma. Bosnian Journal of Basic Medical Sciences, 0, , .	0.6	2
748	Prime Editing: An Emerging Tool in Cancer Treatment. Molecular Biotechnology, 0, , .	1.3	0
749	A novel inflammatory signature for evaluating immune microenvironment status in soft tissue sarcoma. Frontiers in Oncology, 0, 12, .	1.3	0
750	Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study. Clinical Chemistry and Laboratory Medicine, 2022, .	1.4	0

#	Article	IF	Citations
751	Optogenetic-controlled immunotherapeutic designer cells for post-surgical cancer immunotherapy. Nature Communications, 2022, 13, .	5.8	12
752	Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers. Cancers, 2022, 14, 4985.	1.7	5
753	Identification of a ferroptosis-related long non-coding RNA signature for prognosis prediction of ovarian cancer. Carcinogenesis, 2023, 44, 80-92.	1.3	5
754	Tumor microenvironment: barrier or opportunity towards effective cancer therapy. Journal of Biomedical Science, 2022, 29, .	2.6	67
755	Monocyte programming by cancer therapy. Frontiers in Immunology, 0, 13, .	2.2	22
756	PERSONALIZED MEDICINE: AN INNOVATION IN HEALTH-CARE SYSTEM. Asian Journal of Pharmaceutical and Clinical Research, 0, , 4-9.	0.3	0
757	Prognostic value of antitumor drug targets prediction using integrated bioinformatic analysis for immunogenic cell death-related lncRNA model based on stomach adenocarcinoma characteristics and tumor immune microenvironment. Frontiers in Pharmacology, 0, 13, .	1.6	7
758	Transcriptomic discovery of a theranostic signature (SERPINE1/MMP3/COL1A1/SPP1) for head and neck squamous cell carcinomas and identification of antrocinol as a candidate drug. Computers in Biology and Medicine, 2022, 150, 106185.	3.9	2
759	Gundelia tournefortii inhibits hepatocellular carcinoma progression by lowering gene expression of the cell cycle and hepatocyte proliferation in immunodeficient mice. Biomedicine and Pharmacotherapy, 2022, 156, 113885.	2.5	2
760	Tailoring carrier-free nanocombo of small-molecule prodrug for combinational cancer therapy. Journal of Controlled Release, 2022, 352, 256-275.	4.8	13
761	Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects. Biomedicine and Pharmacotherapy, 2023, 157, 113998.	2.5	5
762	Identification of prognostic biomarkers among ICAMs in the breast cancer microenvironment. Cancer Biomarkers, 2022, , 1-15.	0.8	0
763	Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy. Cancers, 2022, 14, 5520.	1.7	10
764	Therapeutic Effects of Anti-PD1 Immunotherapy on Hepatocellular Carcinoma Under Administration of Tacrolimus. Transplantation, 0, Publish Ahead of Print, .	0.5	0
765	Identification of CD73 as a Novel Biomarker Encompassing the Tumor Microenvironment, Prognosis, and Therapeutic Responses in Various Cancers. Cancers, 2022, 14, 5663.	1.7	5
766	Immunotherapy and Targeted Therapy in the Management of Oral Cancers. Critical Reviews in Oncogenesis, 2022, , .	0.2	0
767	A macrophage membrane-coated mesoporous silica nanoplatform inhibiting adenosine A2AR via in situ oxygen supply for immunotherapy. Journal of Controlled Release, 2023, 353, 535-548.	4.8	10
768	Cell delivery devices for cancer immunotherapy. Journal of Controlled Release, 2023, 353, 875-888.	4.8	7

#	Article	IF	Citations
769	Novel strategies for tumor radiosensitization mediated by multifunctional gold-based nanomaterials. Biomaterials Science, 2023, 11, 1116-1136.	2.6	11
770	Exosomes in sarcoma: Prospects for clinical applications. Critical Reviews in Oncology/Hematology, 2023, 181, 103895.	2.0	0
771	An Updated Focus on Immune Checkpoint Inhibitors and Tubulointerstitial Nephritis. , 2023, , 157-184.		0
772	Identification of immune subtypes and their prognosis and molecular implications in colorectal cancer. PLoS ONE, 2022, 17, e0278114.	1.1	0
773	Effects of polybrene and retronectin as transduction enhancers on the development and phenotypic characteristics of VHH-based CD19-redirected CAR T cells: a comparative investigation. Clinical and Experimental Medicine, 2023, 23, 2535-2549.	1.9	3
774	Plasma cell subtypes analyzed using artificial intelligence algorithm for predicting biochemical recurrence, immune escape potential, and immunotherapy response of prostate cancer. Frontiers in Immunology, 0, 13, .	2.2	4
775	Cancer Immunotherapy: The Checkpoint between Chronic Colitis and Colorectal Cancer. Cancers, 2022, 14, 6131.	1.7	9
776	Biomaterials for enhanced immunotherapy. APL Bioengineering, 2022, 6, .	3.3	7
777	Recent advances in the liposomal nanovesicles based immunotherapy in the treatment of cancer: A review. Saudi Pharmaceutical Journal, 2023, 31, 279-294.	1.2	3
778	Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model. Scientific Reports, 2022, 12, .	1.6	3
779	Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma. Current Oncology, 2022, 29, 9813-9825.	0.9	7
780	Recent Developments in the Study of the Microenvironment of Cancer and Drug Delivery. Current Drug Metabolism, 2022, 23, 1027-1053.	0.7	0
781	A novel fatty acid metabolism-related gene prognostic signature and candidate drugs for patients with hepatocellular carcinoma. PeerJ, 0, 11, e14622.	0.9	2
782	Drug repurposing: Recent advancements, challenges, and future therapeutics for cancer treatment. Journal of Bacteriology & Mycology Open Access, 2022, 10, 26-30.	0.2	0
783			

#	Article	IF	Citations
787	Oncogenic human virus associated with prostate cancer: molecular epidemiology of Human Papillomavirus and Epstein-Barr virus. , 2023, , 273-288.		0
788	Recent Progress and Prospects of Immunotherapy in Multidrug-Resistant and Metastatic Breast Cancer Treatment. , 2023, , .		0
789	Effect Model of PD-1 Inhibitors on Immune Metabolism of Mito+ T Lymphocytes in Patients with Non-Small Cell Lung Cancer. Advances in Clinical Medicine, 2023, 13, 1038-1047.	0.0	0
790	Targeting Toll-Like Receptors in Cancer Immunotherapy. , 2023, , 1-25.		0
791	Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer. International Review of Cell and Molecular Biology, 2023, , 173-210.	1.6	0
792	Identification of a novel Immune-Related prognostic model for patients with colorectal cancer based on 3 subtypes. Immunobiology, 2023, 228, 152352.	0.8	0
793	Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature. Journal of Ophthalmic Inflammation and Infection, 2023, 13, .	1.2	1
794	The combination of immunotherapy and a glutamine metabolism inhibitor represents an effective therapeutic strategy for advanced and metastatic murine pancreatic adenocarcinoma. International Immunopharmacology, 2023, 118, 110150.	1.7	1
795	Immunoregulatory actions of calf thymus extract (TFXÂ®) in vitro in relation to its effect on expression of mitogen activated protein kinases. International Immunopharmacology, 2023, 118, 109995.	1.7	0
796	Regulating T-cell metabolic reprogramming and blocking PD-1 co-promote personalized postoperative autologous nanovaccines. Biomaterials, 2023, 297, 122104.	5.7	3
798	Clinical efficacy and safety of bispecific antibodies for the treatment of solid tumors: a systematic review and meta-analysis. Expert Review of Anticancer Therapy, 2023, 23, 307-318.	1.1	0
799	Vaccine-like nanomedicine for cancer immunotherapy. Journal of Controlled Release, 2023, 355, 760-778.	4.8	33
800	Comprehensive analysis of the role of ICOS (CD278) in pan-cancer prognosis and immunotherapy. BMC Cancer, 2023, 23, .	1.1	6
801	Palliative Care and Pain Management. , 2023, , 1-20.		0
802	T Cell Microvilli: Finger-Shaped External Structures Linked to the Fate of T Cells. Immune Network, 2023, 23, .	1.6	4
803	Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Reports, 2023, 5, 100719.	2.6	10
804	The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancerâ€"Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. Cancers, 2023, 15, 1642.	1.7	4
805	30th Annual GP2A Medicinal Chemistry Conference. Pharmaceuticals, 2023, 16, 432.	1.7	0

#	Article	IF	Citations
806	Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitorsâ€"A 2023 Update. International Journal of Molecular Sciences, 2023, 24, 5643.	1.8	7
807	Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy. Molecular Cancer Therapeutics, 2023, 22, 807-817.	1.9	3
809	<scp>RHBDF2</scp> is correlated with immune infiltrates in hepatocellular carcinoma and may have potential as a biomarker. FEBS Open Bio, 2023, 13, 881-897.	1.0	0
810	Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases. Cancers, 2023, 15, 1884.	1.7	4
811	Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup. European Journal of Cancer, 2023, 187, 25-35.	1.3	2
812	Recent Developments in Nanoparticleâ€Based Photoâ€Immunotherapy for Cancer Treatment. Small Methods, 2023, 7, .	4.6	4
813	The Impact of Systemic Medications on Retinal Function. Asia-Pacific Journal of Ophthalmology, 2023, 12, 115-157.	1.3	3
814	Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy. Frontiers in Medicine, 0, 10, .	1.2	3
815	Identification of novel immune-related molecular subtypes and a prognosis model to predict thyroid cancer prognosis and drug resistance. Frontiers in Pharmacology, 0, 14, .	1.6	0
816	Overcoming the Limitations of Therapeutic Strategies to Combat Pancreatic Cancer Using Nanotechnology. Current Cancer Drug Targets, 2023, 23, .	0.8	1
817	Evolution-Informed Strategies for Combating Drug Resistance in Cancer. International Journal of Molecular Sciences, 2023, 24, 6738.	1.8	5
818	Integrative analyses of ferroptosis and immune related biomarkers and the osteosarcoma associated mechanisms. Scientific Reports, 2023, 13, .	1.6	3
819	Apoptosis: aJanus bifronsin T-cell immunotherapy. , 2023, 11, e005967.		3
820	Added diagnostic value of routinely measured hematology variables in diagnosing immune checkpoint inhibitor mediated toxicity in the emergency department. Cancer Medicine, 2023, 12, 12462-12469.	1.3	1
821	Development of an endoplasmic reticulum stress-related signature with potential implications in prognosis and immunotherapy in head and neck squamous cell carcinoma. Diagnostic Pathology, 2023, 18, .	0.9	0
826	The Changing Fortune of Cancer Immunotherapy. , 2017, , 97-125.		0
836	Nature Killer T (NKT) Cells in Cancer. , 2023, , 1-25.		0
839	Natural Immunomodulators in Cancer Therapy. , 2023, , 216-242.		0

#	Article	IF	Citations
842	Editorial: The immunosuppressive tumor microenvironment and strategies to revert its immune regulatory milieu for cancer immunotherapy. Frontiers in Immunology, 0, 14, .	2.2	0
846	Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and Oncolysis by Coxsackie Virus A21. Methods in Molecular Biology, 2023, , 319-327.	0.4	0
848	The contribution of automated cytometry in immuno-oncology. Methods in Cell Biology, 2023, , .	0.5	0
876	Targeted Vibration-Induced Necrosis in Liver Cancer Cells using Paramagnetic Microrobots. , 2023, , .		0
889	Precision medicine: success stories and challenges from science to implementation. , 2024, , 83-113.		0
891	Biomaterials to enhance adoptive cell therapy. , 0, , .		0
893	Recent advances in light-triggered cancer immunotherapy. Journal of Materials Chemistry B, 2024, 12, 2650-2669.	2.9	0
898	Dendrimer-based nanomedicines for cancer immunotherapy. , 2024, , 317-347.		0
900	A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives. Neurological Sciences, 0, , .	0.9	0
903	Circulating Biomarkers in Oncology: Areas of Application, Critical Issues, and Perspectives. , 2023, , 455-465.		0